TDMS Study 96022-02 Pathology Tables
NTP STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS REPORT: PEIRPT10
LAB: Battelle Columbus TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) DATE: 04/29/04
EXPERIMENT: 96022 TEST: 02 TIME: 09:51:36
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96022
PATHOLOGIST: MISSING CAS: TEFPCBMIX
------------------------------------------------------------------------------------------------------------------------------------
FINAL#1 RATS CTRL. VS TREATED
REASONS FOR REMOVAL: 25018 Dosing Accident
25019 Moribund Sacrifice
25020 Natural Death
25021 Terminal Sacrifice
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE 001 0 NG / 0 UG
INCLUDE 002 80 NG /10 UG
INCLUDE 003 240 NG /30 UG
INCLUDE 004 800 NG /100 UG
INCLUDE 005 2400 NG/300 UG
INCLUDE 006 4000 NG/500 UG
NTP STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS REPORT: PEIRPT10
LAB: Battelle Columbus TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) DATE: 04/29/04
EXPERIMENT: 96022 TEST: 02 TIME: 09:51:36
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96022
PATHOLOGIST: MISSING CAS: TEFPCBMIX
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF TEF EVALUATION (PCB MIXTURE;PCB 126/P
===============================================================
Female Rats
------------
Organ Morphology
----- ----------
Adrenal Cortex Angiectasis
Atrophy
Degeneration Cystic
Hyperplasia
Hypertrophy
Necrosis
Vacuolization Cytoplasmic
Adrenal Medulla Hyperplasia
Blood Vessel: Aorta, Adventitia Inflammation
Bone Marrow Atrophy
Hyperplasia
Brain Hemorrhage
Clitoral Gland Inflammation
Clitoral Gland: Duct Cyst
Esophagus: Muscularis Inflammation
Eye: Retina Atrophy
Harderian Gland Inflammation
Heart Cardiomyopathy
Heart: Coronary Artery Inflammation Chronic
Heart: Epicardium Inflammation
Heart: Myocardium Hemorrhage
Necrosis
Intestine Large, Cecum Edema
Inflammation
Intestine Large, Colon Parasite Metazoan
Intestine Large, Rectum Parasite Metazoan
Kidney Calculus Micro Observation Only
Inflammation
Mineralization
Nephropathy
Kidney: Pelvis Inflammation
Kidney: Transitional Epithelium Hyperplasia
Liver Angiectasis
Basophilic Focus
Cholangiofibrosis
Clear Cell Focus
Eosinophilic Focus
Fatty Change Diffuse
Fatty Change Focal
Hematopoietic Cell Proliferation
Hyperplasia
Inflammation
Metaplasia
Mixed Cell Focus
Necrosis
Pigmentation
Toxic Hepatopathy
Liver: Bile Duct Cyst
NTP STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS REPORT: PEIRPT10
LAB: Battelle Columbus TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) DATE: 04/29/04
EXPERIMENT: 96022 TEST: 02 TIME: 09:51:36
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96022
PATHOLOGIST: MISSING CAS: TEFPCBMIX
Fibrosis
Hyperplasia
Liver: Centrilobular Degeneration
Fibrosis
Liver: Hepatocyte Glandular Structures
Hypertrophy
Multinucleated
Liver: Oval Cell Hyperplasia
Liver: Portal Fibrosis
Lung Hemorrhage
Infiltration Cellular Histiocyte
Inflammation
Metaplasia
Lung: Alveolar Epithelium Hyperplasia
Metaplasia Bronchiolar
Lung: Serosa Fibrosis
Lymph Node, Mandibular Ectasia
Hemorrhage
Hyperplasia
Hyperplasia Lymphoid
Lymph Node, Mesenteric Ectasia
Hemorrhage
Hyperplasia
Lymph Node: Mediastinal Ectasia
Hemorrhage
Hyperplasia
Pigmentation
Lymph Node: Pancreatic Hemorrhage
Hyperplasia
Hyperplasia Lymphoid
Lymph Node: Renal Hyperplasia
Mammary Gland Hyperplasia
Inflammation Granulomatous
Mesentery: Artery Inflammation Chronic
Mesentery: Fat Necrosis
Nose Inflammation
Nose: Glands Hyperplasia
Nose: Olfactory Epithelium Metaplasia
Nose: Respiratory Epithelium Hyperplasia
Nose: Squamous Epithelium Hyperplasia
Oral Mucosa: Gingival Hyperplasia
Ovary Atrophy
Cyst
Pancreas Edema
Hemorrhage
Inflammation Chronic
Pancreas: Acinus Atrophy
Vacuolization Cytoplasmic
Pancreas: Artery Inflammation Chronic
Pancreas: Duct Dilatation
Pituitary Gland Angiectasis
Pituitary Gland: Pars Distalis Hyperplasia
Skin Cyst Epithelial Inclusion
Spleen Hematopoietic Cell Proliferation
Pigmentation
Spleen: Lymphoid Follicle Atrophy
Spleen: Red Pulp Atrophy
Stomach, Forestomach Edema
NTP STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS REPORT: PEIRPT10
LAB: Battelle Columbus TEF EVALUATION (PCB MIXTURE;PCB 126/PCB 118) DATE: 04/29/04
EXPERIMENT: 96022 TEST: 02 TIME: 09:51:36
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: NO1-ES-75411 ROUTE: GAVAGE NTP C#: C96022
PATHOLOGIST: MISSING CAS: TEFPCBMIX
Hyperplasia
Mineralization
Stomach, Glandular Erosion
Hemorrhage
Mineralization
Thymus Atrophy
Thyroid Gland: C-Cell Hyperplasia
Thyroid Gland: Follicular Cell Hyperplasia
Hypertrophy
Urinary Bladder Inflammation
Urinary Bladder: Transitional Epithelium
Hyperplasia
Uterus Adenomyosis
Hemorrhage
Inflammation
Inflammation Chronic
Metaplasia
Uterus: Endometrium Hyperplasia Cystic
===============================================================
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 1
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Angiectasis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 42/53 (79%) 35/51 (69%) 39/53 (74%) 25/53 (47%) 4/53 (8%) 6/65 (9%) |
|POLY-3 RATE (b) | 42/48.03 35/42.89 39/47.84 25/42.51 4/25.64 6/14.36 |
|POLY-3 PERCENT (g) | 87.4% 81.6% 81.5% 58.8% 15.6% 41.8% |
|TERMINAL (d) | 26/27 (96%) 16/17 (94%) 21/24 (88%) 11/15 (73%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 482 70 63 390 450 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.515N P=0.132 P=0.432 P=0.322N P=0.342N P=0.008 ** |
|POLY 3 | P<0.001N** P=0.292N P=0.281N P<0.001N** P<0.001N** P<0.001N** |
|POLY 1.5 | P<0.001N** P=0.211N P=0.273N P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.401N P=0.311N P<0.001N** P<0.001N** P=0.249N |
|LOGISTIC REGRESSION| P<0.001N** P=0.381N P=0.447N P=0.002N** P<0.001N** P=0.007N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.156N P=0.324N P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 1/51 (2%) 0/53 (0%) 15/53 (28%) 44/53 (83%) 40/65 (62%) |
|POLY-3 RATE (b) | 2/42.18 1/33.36 0/37.79 15/39.73 44/45.82 40/41.82 |
|POLY-3 PERCENT (g) | 4.7% 3.0% 0.0% 37.8% 96.0% 95.7% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 0/24 (0%) 5/15 (33%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 649 443 --- 534 349 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.614N P=0.273N P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.581N P=0.262N P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.560N P=0.253N P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.603N P=0.272N P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.494N P=0.260N P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.515N P=0.248N P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 2
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Degeneration Cystic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 12/53 (23%) 12/51 (24%) 13/53 (25%) 11/53 (21%) 6/53 (11%) 2/65 (3%) |
|POLY-3 RATE (b) | 12/43.80 12/34.17 13/40.71 11/40.47 6/27.37 2/10.85 |
|POLY-3 PERCENT (g) | 27.4% 35.1% 31.9% 27.2% 21.9% 18.4% |
|TERMINAL (d) | 6/27 (22%) 7/17 (41%) 7/24 (29%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 482 541 408 534 482 336 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.017 * P=0.189 P=0.368 P=0.359 P=0.094 P=0.152 |
|POLY 3 | P=0.186N P=0.313 P=0.413 P=0.589N P=0.409N P=0.442N |
|POLY 1.5 | P=0.031N* P=0.386 P=0.444 P=0.566N P=0.240N P=0.116N |
|POLY 6 | P=0.467N P=0.249 P=0.382 P=0.580 P=0.547 P=0.479 |
|LOGISTIC REGRESSION| P=0.044N* P=0.312 P=0.440 P=0.551N P=0.255N P=0.396N |
|COCH-ARM / FISHERS | P<0.001N** P=0.549 P=0.500 P=0.500N P=0.098N P<0.001N** |
|ORDER RESTRICTED | P=0.540N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 13/53 (25%) 7/51 (14%) 13/53 (25%) 12/53 (23%) 10/53 (19%) 5/65 (8%) |
|POLY-3 RATE (b) | 13/44.54 7/34.51 13/40.27 12/39.26 10/28.88 5/13.17 |
|POLY-3 PERCENT (g) | 29.2% 20.3% 32.3% 30.6% 34.6% 38.0% |
|TERMINAL (d) | 5/27 (19%) 3/17 (18%) 9/24 (38%) 5/15 (33%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 362 436 455 552 267 321 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.391N P=0.444 P=0.295 P=0.005 ** P=0.004 ** |
|POLY 3 | P=0.222 P=0.261N P=0.470 P=0.541 P=0.409 P=0.423 |
|POLY 1.5 | P=0.490N P=0.210N P=0.515 P=0.587 P=0.578N P=0.368N |
|POLY 6 | P=0.048 * P=0.318N P=0.419 P=0.470 P=0.167 P=0.195 |
|LOGISTIC REGRESSION| P=0.531N P=0.178N P=0.539 P=0.579N P=0.452N P=0.532N |
|COCH-ARM / FISHERS | P=0.014N* P=0.125N P=0.589N P=0.500N P=0.319N P=0.011N* |
|ORDER RESTRICTED | P=0.487 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 3
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Hypertrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 45/53 (85%) 40/51 (78%) 47/53 (89%) 44/53 (83%) 45/53 (85%) 27/65 (42%) |
|POLY-3 RATE (b) | 45/48.89 40/44.19 47/48.81 44/47.04 45/46.85 27/31.15 |
|POLY-3 PERCENT (g) | 92.1% 90.5% 96.3% 93.5% 96.1% 86.7% |
|TERMINAL (d) | 26/27 (96%) 15/17 (88%) 24/24 (100%) 14/15 (93%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 328 399 390 337 174 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.067 P=0.148 P=0.017 * P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.480N P=0.549N P=0.278 P=0.555 P=0.305 P=0.303N |
|POLY 1.5 | P=0.011N* P=0.522N P=0.290 P=0.541 P=0.393 P=0.006N** |
|POLY 6 | P=0.219 P=0.495N P=0.294 P=0.604 P=0.268 P=0.635 |
|LOGISTIC REGRESSION| P=0.308 P=0.480 P=0.167 P=0.422 P=0.057 P=0.527 |
|COCH-ARM / FISHERS | P<0.001N** P=0.274N P=0.388 P=0.500N P=0.607N P<0.001N** |
|ORDER RESTRICTED | P=0.129N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Necrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 0/51 (0%) 2/53 (4%) 4/53 (8%) 1/53 (2%) 4/65 (6%) |
|POLY-3 RATE (b) | 1/42.24 0/32.58 2/39.10 4/38.53 1/24.86 4/13.13 |
|POLY-3 PERCENT (g) | 2.4% 0.0% 5.1% 10.4% 4.0% 30.5% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 628 --- 426 548 313 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.003 ** P=0.571N P=0.457 P=0.139 P=0.649 P=0.077 |
|POLY 3 | P=0.037 * P=0.551N P=0.473 P=0.151 P=0.630 P=0.028 * |
|POLY 1.5 | P=0.062 P=0.537N P=0.483 P=0.159 P=0.693 P=0.063 |
|POLY 6 | P=0.014 * P=0.566N P=0.463 P=0.137 P=0.533 P=0.016 * |
|LOGISTIC REGRESSION| P=0.486N P=0.512N P=0.571 P=0.202 P=0.607N P=0.627N |
|COCH-ARM / FISHERS | P=0.172 P=0.510N P=0.500 P=0.181 P=0.752N P=0.252 |
|ORDER RESTRICTED | P=0.005 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 4
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Vacuolization Cytoplasmic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 14/53 (26%) 16/51 (31%) 13/53 (25%) 24/53 (45%) 27/53 (51%) 12/65 (18%) |
|POLY-3 RATE (b) | 14/44.09 16/36.76 13/41.07 24/41.43 27/36.88 12/18.81 |
|POLY-3 PERCENT (g) | 31.8% 43.5% 31.7% 57.9% 73.2% 63.8% |
|TERMINAL (d) | 6/27 (22%) 7/17 (41%) 7/24 (29%) 10/15 (67%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 564 70 443 539 313 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.092 P=0.516 P=0.002 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.191 P=0.589N P=0.010 * P<0.001 ** P=0.034 * |
|POLY 1.5 | P=0.003 ** P=0.243 P=0.555N P=0.014 * P<0.001 ** P=0.223 |
|POLY 6 | P<0.001 ** P=0.149 P=0.560 P=0.005 ** P<0.001 ** P=0.006 ** |
|LOGISTIC REGRESSION| P=0.007 ** P=0.246 P=0.560N P=0.011 * P<0.001 ** P=0.266 |
|COCH-ARM / FISHERS | P=0.294N P=0.366 P=0.500N P=0.034 * P=0.008 ** P=0.208N |
|ORDER RESTRICTED | P=0.011 * (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 13/53 (25%) 4/51 (8%) 9/53 (17%) 12/53 (23%) 2/53 (4%) 0/64 (0%) |
|POLY-3 RATE (b) | 13/42.77 4/32.97 9/38.63 12/38.98 2/24.72 0/9.22 |
|POLY-3 PERCENT (g) | 30.4% 12.1% 23.3% 30.8% 8.1% 0.0% |
|TERMINAL (d) | 10/27 (37%) 3/17 (18%) 7/24 (29%) 4/15 (27%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 628 616 567 552 525 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.123 P=0.112N P=0.353N P=0.220 P=0.363 P=0.999N |
|POLY 3 | P=0.079N P=0.051N P=0.317N P=0.581 P=0.039N* P=0.166N |
|POLY 1.5 | P=0.007N** P=0.038N* P=0.285N P=0.576N P=0.011N* P=0.015N* |
|POLY 6 | P=0.383N P=0.070N P=0.353N P=0.532 P=0.164N P=0.440N |
|LOGISTIC REGRESSION| P=0.187N P=0.072N P=0.358N P=0.491 P=0.231N P=0.612N |
|COCH-ARM / FISHERS | P<0.001N** P=0.020N* P=0.237N P=0.500N P=0.002N** P<0.001N** |
|ORDER RESTRICTED | P=0.186N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 5
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Blood Vessel: Aorta, Adventitia |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/52 (0%) 0/53 (0%) 1/53 (2%) 2/66 (3%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.04 0/36.73 1/24.55 2/11.08 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 4.1% 18.1% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- 530 294 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) (e) P=0.409 P=0.123 |
|POLY 3 | P=0.022 * (e) (e) (e) P=0.400 P=0.095 |
|POLY 1.5 | P=0.014 * (e) (e) (e) P=0.443 P=0.136 |
|POLY 6 | P=0.038 * (e) (e) (e) P=0.343 P=0.077 |
|LOGISTIC REGRESSION| P=0.093 (e) (e) (e) P=0.589 P=0.609 |
|COCH-ARM / FISHERS | P=0.020 * (e) (e) (e) P=0.500 P=0.306 |
|ORDER RESTRICTED | P=0.004 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Bone Marrow |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 2/53 (4%) 12/66 (18%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 2/25.71 12/20.74 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 7.8% 57.9% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- 313 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) (e) P=0.231 P<0.001 ** |
|POLY 3 | P<0.001 ** (e) (e) (e) P=0.149 P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) (e) (e) P=0.184 P<0.001 ** |
|POLY 6 | P<0.001 ** (e) (e) (e) P=0.110 P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) (e) (e) P=0.495 P=0.387 |
|COCH-ARM / FISHERS | P<0.001 ** (e) (e) (e) P=0.248 P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 6
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Bone Marrow |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 37/53 (70%) 41/51 (80%) 36/53 (68%) 48/53 (91%) 47/53 (89%) 49/66 (74%) |
|POLY-3 RATE (b) | 37/51.61 41/49.07 36/50.24 48/52.21 47/48.90 49/50.11 |
|POLY-3 PERCENT (g) | 71.7% 83.6% 71.7% 91.9% 96.1% 97.8% |
|TERMINAL (d) | 14/27 (52%) 10/17 (59%) 12/24 (50%) 13/15 (87%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 70 63 41 166 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.022 * P=0.371 P=0.002 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.112 P=0.586N P=0.005 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.121 P=0.560N P=0.006 ** P<0.001 ** P=0.002 ** |
|POLY 6 | P<0.001 ** P=0.113 P=0.576 P=0.005 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P=0.503 P=0.338 P=0.360N P=0.021 * P=0.069 P=0.298 |
|COCH-ARM / FISHERS | P=0.328 P=0.154 P=0.500N P=0.007 ** P=0.015 * P=0.369 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Brain |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 1/53 (2%) 4/53 (8%) 5/53 (9%) 14/66 (21%) |
|POLY-3 RATE (b) | 0/41.89 1/33.49 1/37.79 4/38.75 5/28.06 14/22.64 |
|POLY-3 PERCENT (g) | 0.0% 3.0% 2.7% 10.3% 17.8% 61.8% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 328 726 (T) 78 313 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.488 P=0.477 P=0.047 * P=0.026 * P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.456 P=0.479 P=0.050 P=0.009 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.467 P=0.487 P=0.054 P=0.016 * P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.444 P=0.472 P=0.044 * P=0.004 ** P<0.001 ** |
|LOGISTIC REGRESSION| P=0.044 * P=0.724 P=0.477 P=0.103 P=0.160 P=0.402 |
|COCH-ARM / FISHERS | P<0.001 ** P=0.490 P=0.500 P=0.059 P=0.028 * P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 7
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Brain |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 2/53 (4%) 1/53 (2%) 0/66 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 2/38.16 1/24.47 0/9.33 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.2% 4.1% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 78 565 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.360 (e) (e) P=0.220 P=0.379 (e) |
|POLY 3 | P=0.121 (e) (e) P=0.216 P=0.399 (e) |
|POLY 1.5 | P=0.294 (e) (e) P=0.225 P=0.443 (e) |
|POLY 6 | P=0.032 * (e) (e) P=0.203 P=0.343 (e) |
|LOGISTIC REGRESSION| P=0.319N (e) (e) P=0.416 P=0.546 (e) |
|COCH-ARM / FISHERS | P=0.603N (e) (e) P=0.248 P=0.500 (e) |
|ORDER RESTRICTED | P=0.534 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Brain |
| Necrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 2/53 (4%) 1/53 (2%) 0/66 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 2/38.16 1/24.47 0/9.33 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.2% 4.1% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 78 565 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.360 (e) (e) P=0.220 P=0.379 (e) |
|POLY 3 | P=0.121 (e) (e) P=0.216 P=0.399 (e) |
|POLY 1.5 | P=0.294 (e) (e) P=0.225 P=0.443 (e) |
|POLY 6 | P=0.032 * (e) (e) P=0.203 P=0.343 (e) |
|LOGISTIC REGRESSION| P=0.319N (e) (e) P=0.416 P=0.546 (e) |
|COCH-ARM / FISHERS | P=0.603N (e) (e) P=0.248 P=0.500 (e) |
|ORDER RESTRICTED | P=0.534 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 8
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Clitoral Gland |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 49/53 (92%) 44/51 (86%) 46/51 (90%) 34/52 (65%) 21/52 (40%) 31/66 (47%) |
|POLY-3 RATE (b) | 49/52.29 44/48.11 46/49.70 34/45.57 21/35.74 31/35.89 |
|POLY-3 PERCENT (g) | 93.7% 91.5% 92.6% 74.6% 58.8% 86.4% |
|TERMINAL (d) | 24/27 (89%) 16/17 (94%) 22/24 (92%) 10/15 (67%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 70 63 390 267 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.078 P=0.403 P=0.534N P=0.014 * P<0.001 ** |
|POLY 3 | P<0.001N** P=0.479N P=0.569N P=0.005N** P<0.001N** P=0.160N |
|POLY 1.5 | P<0.001N** P=0.390N P=0.518N P=0.002N** P<0.001N** P<0.001N** |
|POLY 6 | P=0.083N P=0.570N P=0.657N P=0.015N* P<0.001N** P=0.532 |
|LOGISTIC REGRESSION| P<0.001N** P=0.272N P=0.454N P<0.001N** P<0.001N** P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.241N P=0.475N P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Clitoral Gland: Duct |
| Cyst |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 40/53 (75%) 41/51 (80%) 43/51 (84%) 45/52 (87%) 48/52 (92%) 61/66 (92%) |
|POLY-3 RATE (b) | 40/50.23 41/46.05 43/48.26 45/49.78 48/49.06 61/61.31 |
|POLY-3 PERCENT (g) | 79.6% 89.0% 89.1% 90.4% 97.9% 99.5% |
|TERMINAL (d) | 20/27 (74%) 17/17 (100%) 21/24 (88%) 13/15 (87%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 313 78 399 41 166 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.019 * P=0.156 P=0.008 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.145 P=0.144 P=0.096 P=0.002 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.210 P=0.147 P=0.110 P=0.004 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.079 P=0.139 P=0.073 P=0.002 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.268 P=0.158 P=0.117 P=0.010 * P=0.017 * |
|COCH-ARM / FISHERS | P=0.004 ** P=0.357 P=0.190 P=0.116 P=0.018 * P=0.010 * |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 9
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Esophagus: Muscularis |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 3/53 (6%) 0/51 (0%) 2/53 (4%) 3/53 (6%) 3/53 (6%) 2/66 (3%) |
|POLY-3 RATE (b) | 3/42.85 0/32.58 2/38.52 3/37.73 3/26.07 2/10.61 |
|POLY-3 PERCENT (g) | 7.0% 0.0% 5.2% 8.0% 11.5% 18.9% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 1/24 (4%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 --- 471 78 373 254 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.005 ** P=0.198N P=0.562N P=0.503 P=0.291 P=0.066 |
|POLY 3 | P=0.094 P=0.175N P=0.549N P=0.603 P=0.424 P=0.347 |
|POLY 1.5 | P=0.186 P=0.157N P=0.530N P=0.628 P=0.532 P=0.556 |
|POLY 6 | P=0.049 * P=0.195N P=0.568N P=0.561 P=0.285 P=0.234 |
|LOGISTIC REGRESSION| P=0.469N P=0.125N P=0.477N P=0.592N P=0.510N P=0.783 |
|COCH-ARM / FISHERS | P=0.538 P=0.129N P=0.500N P=0.661N P=0.661N P=0.397N |
|ORDER RESTRICTED | P=0.245 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Eye |
| Cataract |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 3/51 (6%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 1/42.21 3/33.49 0/37.79 0/36.73 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 2.4% 9.0% 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 2/17 (12%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 639 328 --- --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.267N P=0.199 P=0.541N P=0.541N P=0.713N P=1.000N |
|POLY 3 | P=0.164N P=0.227 P=0.522N P=0.528N P=0.605N P=0.697N |
|POLY 1.5 | P=0.142N P=0.247 P=0.514N P=0.518N P=0.559N P=0.626N |
|POLY 6 | P=0.162N P=0.206 P=0.531N P=0.544N P=0.664N P=0.735N |
|LOGISTIC REGRESSION| P=0.064N P=0.306 P=0.499N P=0.502N P=0.593N P=0.905N |
|COCH-ARM / FISHERS | P=0.074N P=0.294 P=0.500N P=0.500N P=0.500N P=0.445N |
|ORDER RESTRICTED | P=0.499N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 10
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Eye: Retina |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 3/51 (6%) 0/53 (0%) 1/53 (2%) 0/53 (0%) 1/66 (2%) |
|POLY-3 RATE (b) | 1/42.21 3/32.89 0/37.79 1/36.73 0/23.94 1/9.73 |
|POLY-3 PERCENT (g) | 2.4% 9.1% 0.0% 2.7% 0.0% 10.3% |
|TERMINAL (d) | 0/27 (0%) 2/17 (12%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 639 642 --- 726 (T) --- 611 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.054 P=0.180 P=0.541N P=0.671 P=0.713N P=0.016 * |
|POLY 3 | P=0.438N P=0.222 P=0.522N P=0.729 P=0.605N P=0.442 |
|POLY 1.5 | P=0.414N P=0.243 P=0.514N P=0.741 P=0.559N P=0.580 |
|POLY 6 | P=0.443N P=0.202 P=0.531N P=0.709 P=0.664N P=0.358 |
|LOGISTIC REGRESSION| P=0.371 P=0.216 P=0.499N P=0.734 P=0.593N P=0.457 |
|COCH-ARM / FISHERS | P=0.263N P=0.294 P=0.500N P=0.752N P=0.500N P=0.694N |
|ORDER RESTRICTED | P=0.405 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Harderian Gland |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 24/53 (45%) 7/51 (14%) 20/53 (38%) 13/53 (25%) 7/53 (13%) 9/66 (14%) |
|POLY-3 RATE (b) | 24/45.26 7/34.66 20/40.69 13/38.18 7/27.04 9/16.65 |
|POLY-3 PERCENT (g) | 53.0% 20.2% 49.2% 34.1% 25.9% 54.1% |
|TERMINAL (d) | 15/27 (56%) 1/17 (6%) 13/24 (54%) 7/15 (47%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 313 541 455 567 523 217 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.023N* P=0.479N P=0.356N P=0.082 P<0.001 ** |
|POLY 3 | P=0.216N P=0.002N** P=0.441N P=0.056N P=0.020N* P=0.571 |
|POLY 1.5 | P=0.045N* P<0.001N** P=0.378N P=0.039N* P=0.003N** P=0.111N |
|POLY 6 | P=0.489 P=0.003N** P=0.510N P=0.100N P=0.155N P=0.194 |
|LOGISTIC REGRESSION| P=0.484N P=0.002N** P=0.415N P=0.054N P=0.030N* P=0.329N |
|COCH-ARM / FISHERS | P<0.001N** P<0.001N** P=0.277N P=0.020N* P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.266N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 11
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Heart |
| Cardiomyopathy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 20/53 (38%) 13/51 (25%) 17/53 (32%) 34/53 (64%) 14/53 (26%) 19/65 (29%) |
|POLY-3 RATE (b) | 20/45.03 13/36.13 17/42.28 34/44.99 14/30.44 19/24.56 |
|POLY-3 PERCENT (g) | 44.4% 36.0% 40.2% 75.6% 46.0% 77.4% |
|TERMINAL (d) | 11/27 (41%) 3/17 (18%) 7/24 (29%) 10/15 (67%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 525 408 537 447 237 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.531N P=0.526N P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.006 ** P=0.292N P=0.427N P<0.001 ** P=0.540 P=0.009 ** |
|POLY 1.5 | P=0.124 P=0.236N P=0.395N P<0.001 ** P=0.402N P=0.125 |
|POLY 6 | P<0.001 ** P=0.335N P=0.456N P<0.001 ** P=0.244 P<0.001 ** |
|LOGISTIC REGRESSION| P=0.038 * P=0.266N P=0.406N P<0.001 ** P=0.566 P=0.117 |
|COCH-ARM / FISHERS | P=0.108N P=0.129N P=0.342N P=0.006 ** P=0.149N P=0.217N |
|ORDER RESTRICTED | P=0.003 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Heart: Coronary Artery |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 1/51 (2%) 0/53 (0%) 7/53 (13%) 10/53 (19%) 9/65 (14%) |
|POLY-3 RATE (b) | 1/41.89 1/32.58 0/37.79 7/37.65 10/29.16 9/16.16 |
|POLY-3 PERCENT (g) | 2.4% 3.1% 0.0% 18.6% 34.3% 55.7% |
|TERMINAL (d) | 1/27 (4%) 1/17 (6%) 0/24 (0%) 3/15 (20%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 726 (T) --- 567 450 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.656 P=0.523N P=0.006 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.702 P=0.521N P=0.019 * P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.719 P=0.513N P=0.023 * P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.685 P=0.528N P=0.015 * P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.656 (e) P=0.015 * P=0.005 ** P=0.007 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.743 P=0.500N P=0.030 * P=0.004 ** P=0.019 * |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 12
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Heart: Epicardium |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 1/51 (2%) 0/53 (0%) 6/53 (11%) 13/53 (25%) 6/65 (9%) |
|POLY-3 RATE (b) | 1/42.60 1/33.49 0/37.79 6/38.00 13/30.80 6/13.78 |
|POLY-3 PERCENT (g) | 2.4% 3.0% 0.0% 15.8% 42.2% 43.5% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 482 328 --- 619 313 362 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.732 P=0.525N P=0.028 * P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.705 P=0.524N P=0.038 * P<0.001 ** P=0.003 ** |
|POLY 1.5 | P<0.001 ** P=0.721 P=0.515N P=0.044 * P<0.001 ** P=0.009 ** |
|POLY 6 | P<0.001 ** P=0.688 P=0.533N P=0.032 * P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.608N P=0.431N P=0.054 P=0.003 ** P=0.087 |
|COCH-ARM / FISHERS | P=0.002 ** P=0.743 P=0.500N P=0.056 P<0.001 ** P=0.096 |
|ORDER RESTRICTED | P=0.002 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Heart: Myocardium |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 3/65 (5%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 0/23.94 3/12.08 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 0.0% 24.8% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- --- 267 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) (e) (e) P=0.084 |
|POLY 3 | P=0.029 * (e) (e) (e) (e) P=0.030 * |
|POLY 1.5 | P=0.009 ** (e) (e) (e) (e) P=0.051 |
|POLY 6 | P=0.063 (e) (e) (e) (e) P=0.022 * |
|LOGISTIC REGRESSION| P=0.074 (e) (e) (e) (e) P=0.655 |
|COCH-ARM / FISHERS | P=0.004 ** (e) (e) (e) (e) P=0.164 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 13
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Heart: Myocardium |
| Necrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 2/65 (3%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 0/23.94 2/11.19 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 0.0% 17.9% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- --- 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.012 * (e) (e) (e) (e) P=0.229 |
|POLY 3 | P=0.101 (e) (e) (e) (e) P=0.094 |
|POLY 1.5 | P=0.042 * (e) (e) (e) (e) P=0.135 |
|POLY 6 | P=0.193 (e) (e) (e) (e) P=0.076 |
|LOGISTIC REGRESSION| P=0.151 (e) (e) (e) (e) P=0.890 |
|COCH-ARM / FISHERS | P=0.019 * (e) (e) (e) (e) P=0.301 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Intestine Large, Cecum |
| Edema |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/52 (0%) 2/65 (3%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 0/23.71 2/11.19 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 0.0% 17.9% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- --- 254 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.012 * (e) (e) (e) (e) P=0.229 |
|POLY 3 | P=0.103 (e) (e) (e) (e) P=0.094 |
|POLY 1.5 | P=0.042 * (e) (e) (e) (e) P=0.135 |
|POLY 6 | P=0.194 (e) (e) (e) (e) P=0.076 |
|LOGISTIC REGRESSION| P=0.151 (e) (e) (e) (e) P=0.865 |
|COCH-ARM / FISHERS | P=0.019 * (e) (e) (e) (e) P=0.301 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 14
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Intestine Large, Cecum |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/52 (0%) 2/65 (3%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 0/23.71 2/11.20 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 0.0% 17.9% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- --- 233 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.014 * (e) (e) (e) (e) P=0.243 |
|POLY 3 | P=0.102 (e) (e) (e) (e) P=0.094 |
|POLY 1.5 | P=0.042 * (e) (e) (e) (e) P=0.135 |
|POLY 6 | P=0.194 (e) (e) (e) (e) P=0.076 |
|LOGISTIC REGRESSION| P=0.151 (e) (e) (e) (e) P=0.887 |
|COCH-ARM / FISHERS | P=0.019 * (e) (e) (e) (e) P=0.301 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Intestine Large, Cecum: Artery |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 2/53 (4%) 0/52 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 2/37.26 0/23.71 0/9.28 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.4% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 567 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.505 (e) (e) P=0.165 (e) (e) |
|POLY 3 | P=0.448 (e) (e) P=0.211 (e) (e) |
|POLY 1.5 | P=0.641 (e) (e) P=0.220 (e) (e) |
|POLY 6 | P=0.182 (e) (e) P=0.198 (e) (e) |
|LOGISTIC REGRESSION| P=0.730N (e) (e) P=0.229 (e) (e) |
|COCH-ARM / FISHERS | P=0.442N (e) (e) P=0.248 (e) (e) |
|ORDER RESTRICTED | P=0.589 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 15
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Intestine Large, Colon |
| Parasite Metazoan |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 1/51 (2%) 0/53 (0%) 0/53 (0%) 0/52 (0%) 2/65 (3%) |
|POLY-3 RATE (b) | 2/41.97 1/33.04 0/37.79 0/36.73 0/23.71 2/11.13 |
|POLY-3 PERCENT (g) | 4.8% 3.0% 0.0% 0.0% 0.0% 18.0% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 707 594 --- --- --- 236 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.038 * P=0.635N P=0.269N P=0.356N P=0.962N P=0.175 |
|POLY 3 | P=0.590 P=0.582N P=0.261N P=0.268N P=0.379N P=0.283 |
|POLY 1.5 | P=0.483 P=0.561N P=0.252N P=0.256N P=0.313N P=0.444 |
|POLY 6 | P=0.505N P=0.603N P=0.270N P=0.287N P=0.480N P=0.197 |
|LOGISTIC REGRESSION| P=0.537 P=0.580N P=0.269N P=0.317N P=0.802N P=0.807N |
|COCH-ARM / FISHERS | P=0.443 P=0.515N P=0.248N P=0.248N P=0.252N P=0.610N |
|ORDER RESTRICTED | P=0.036 * (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Intestine Large, Rectum |
| Parasite Metazoan |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 3/52 (6%) 2/51 (4%) 2/53 (4%) 2/53 (4%) 1/52 (2%) 0/66 (0%) |
|POLY-3 RATE (b) | 3/41.84 2/33.62 2/38.04 2/37.00 1/24.57 0/9.33 |
|POLY-3 PERCENT (g) | 7.2% 6.0% 5.3% 5.4% 4.1% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 567 541 659 687 373 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.618 P=0.657N P=0.559N P=0.667N P=0.702 P=0.987N |
|POLY 3 | P=0.357N P=0.599N P=0.543N P=0.556N P=0.508N P=0.482N |
|POLY 1.5 | P=0.205N P=0.571N P=0.524N P=0.532N P=0.413N P=0.300N |
|POLY 6 | P=0.504N P=0.625N P=0.564N P=0.593N P=0.639N P=0.604N |
|LOGISTIC REGRESSION| P=0.109N P=0.516N P=0.529N P=0.546N P=0.273N P=0.613N |
|COCH-ARM / FISHERS | P=0.043N* P=0.509N P=0.491N P=0.491N P=0.309N P=0.083N |
|ORDER RESTRICTED | P=0.548N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 16
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Intestine Large, Rectum: Artery |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/52 (0%) 1/51 (2%) 1/53 (2%) 3/53 (6%) 1/52 (2%) 0/66 (0%) |
|POLY-3 RATE (b) | 0/41.24 1/32.58 1/37.79 3/37.69 1/24.26 0/9.33 |
|POLY-3 PERCENT (g) | 0.0% 3.1% 2.7% 8.0% 4.1% 0.0% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 1/24 (4%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) 726 (T) 567 555 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.109 P=0.408 P=0.477 P=0.079 P=0.386 (e) |
|POLY 3 | P=0.279 P=0.453 P=0.483 P=0.103 P=0.400 (e) |
|POLY 1.5 | P=0.528 P=0.467 P=0.491 P=0.109 P=0.444 (e) |
|POLY 6 | P=0.089 P=0.439 P=0.474 P=0.093 P=0.344 (e) |
|LOGISTIC REGRESSION| P=0.569 P=0.408 P=0.477 P=0.122 P=0.560 (e) |
|COCH-ARM / FISHERS | P=0.270N P=0.495 P=0.505 P=0.125 P=0.500 (e) |
|ORDER RESTRICTED | P=0.547 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Kidney |
| Calculus Micro Observation Only |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 6/53 (11%) 6/51 (12%) 6/53 (11%) 0/53 (0%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 6/42.65 6/32.84 6/39.15 0/36.73 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 14.1% 18.3% 15.3% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 4/27 (15%) 5/17 (29%) 3/24 (13%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 586 659 443 --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.066N P=0.313 P=0.530 P=0.055N P=0.508N P=0.985N |
|POLY 3 | P=0.005N** P=0.430 P=0.560 P=0.024N* P=0.082N P=0.343N |
|POLY 1.5 | P=0.002N** P=0.484 P=0.583 P=0.021N* P=0.040N* P=0.128N |
|POLY 6 | P=0.008N** P=0.375 P=0.538 P=0.032N* P=0.193N P=0.532N |
|LOGISTIC REGRESSION| P=0.008N** P=0.382 P=0.575 P=0.027N* P=0.129N P=0.561N |
|COCH-ARM / FISHERS | P<0.001N** P=0.592 P=0.620N P=0.013N* P=0.013N* P=0.007N** |
|ORDER RESTRICTED | P=0.334N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 17
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Kidney |
| Cyst |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 2/51 (4%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 0/41.89 2/33.36 0/37.79 0/36.73 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 0.0% 6.0% 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 443 --- --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.443N P=0.173 (e) (e) (e) (e) |
|POLY 3 | P=0.365N P=0.190 (e) (e) (e) (e) |
|POLY 1.5 | P=0.329N P=0.201 (e) (e) (e) (e) |
|POLY 6 | P=0.362N P=0.178 (e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.189N P=0.248 (e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.208N P=0.238 (e) (e) (e) (e) |
|ORDER RESTRICTED | P=0.607N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Kidney |
| Infarct |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 1/65 (2%) |
|POLY-3 RATE (b) | 2/41.89 0/32.58 0/37.79 0/36.73 0/23.94 1/10.26 |
|POLY-3 PERCENT (g) | 4.8% 0.0% 0.0% 0.0% 0.0% 9.8% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) --- --- --- --- 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.192 P=0.344N P=0.264N P=0.374N P=1.000N P=0.534 |
|POLY 3 | P=0.532N P=0.296N P=0.260N P=0.267N P=0.377N P=0.535 |
|POLY 1.5 | P=0.618N P=0.280N P=0.252N P=0.256N P=0.310N P=0.705 |
|POLY 6 | P=0.383N P=0.314N P=0.269N P=0.286N P=0.478N P=0.417 |
|LOGISTIC REGRESSION| P=0.633N (e) (e) (e) (e) P=0.732N |
|COCH-ARM / FISHERS | P=0.607N P=0.257N P=0.248N P=0.248N P=0.248N P=0.423N |
|ORDER RESTRICTED | P=0.191 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 18
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Kidney |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 4/53 (8%) 3/53 (6%) 0/53 (0%) 1/65 (2%) |
|POLY-3 RATE (b) | 0/41.89 1/32.58 4/38.07 3/37.44 0/23.94 1/10.26 |
|POLY-3 PERCENT (g) | 0.0% 3.1% 10.5% 8.0% 0.0% 9.8% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 3/24 (13%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) 651 594 --- 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.087 P=0.408 P=0.049 * P=0.077 (e) P=0.534 |
|POLY 3 | P=0.568 P=0.450 P=0.048 * P=0.099 (e) P=0.307 |
|POLY 1.5 | P=0.452N P=0.464 P=0.053 P=0.106 (e) P=0.378 |
|POLY 6 | P=0.335 P=0.437 P=0.044 * P=0.090 (e) P=0.268 |
|LOGISTIC REGRESSION| P=0.569N P=0.408 P=0.045 * P=0.107 (e) P=0.996 |
|COCH-ARM / FISHERS | P=0.189N P=0.490 P=0.059 P=0.121 (e) P=0.551 |
|ORDER RESTRICTED | P=0.373 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Kidney |
| Mineralization |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 46/53 (87%) 34/51 (67%) 38/53 (72%) 44/53 (83%) 34/53 (64%) 37/65 (57%) |
|POLY-3 RATE (b) | 46/51.13 34/44.52 38/48.48 44/50.44 34/44.31 37/39.76 |
|POLY-3 PERCENT (g) | 90.0% 76.4% 78.4% 87.2% 76.7% 93.1% |
|TERMINAL (d) | 23/27 (85%) 10/17 (59%) 19/24 (79%) 14/15 (93%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 313 275 63 41 166 217 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.424 P=0.402N P=0.048 * P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.282 P=0.055N P=0.080N P=0.449N P=0.046N* P=0.434 |
|POLY 1.5 | P=0.329N P=0.037N* P=0.057N P=0.398N P=0.015N* P=0.219N |
|POLY 6 | P=0.059 P=0.076N P=0.124N P=0.557N P=0.206N P=0.127 |
|LOGISTIC REGRESSION| P=0.048N* P=0.033N* P=0.055N P=0.397N P=0.004N** P=0.551N |
|COCH-ARM / FISHERS | P<0.001N** P=0.013N* P=0.046N* P=0.393N P=0.006N** P<0.001N** |
|ORDER RESTRICTED | P=0.093 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 19
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Kidney |
| Nephropathy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 41/53 (77%) 37/51 (73%) 37/53 (70%) 48/53 (91%) 50/53 (94%) 43/65 (66%) |
|POLY-3 RATE (b) | 41/49.70 37/43.32 37/46.04 48/49.44 50/50.38 43/44.50 |
|POLY-3 PERCENT (g) | 82.5% 85.4% 80.4% 97.1% 99.3% 96.6% |
|TERMINAL (d) | 24/27 (89%) 14/17 (82%) 21/24 (88%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 328 63 41 267 91 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.077 P=0.512 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.457 P=0.498N P=0.008 ** P<0.001 ** P=0.013 * |
|POLY 1.5 | P=0.003 ** P=0.520 P=0.394N P=0.013 * P=0.002 ** P=0.144 |
|POLY 6 | P<0.001 ** P=0.466 P=0.593N P=0.008 ** P=0.003 ** P=0.006 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.552 P=0.326N P=0.025 * P=0.003 ** P=0.133 |
|COCH-ARM / FISHERS | P=0.321N P=0.367N P=0.255N P=0.055 P=0.012 * P=0.128N |
|ORDER RESTRICTED | P=0.002 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Kidney: Pelvis |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 6/51 (12%) 1/53 (2%) 6/53 (11%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 4/42.25 6/34.63 1/37.79 6/38.27 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 9.5% 17.3% 2.7% 15.7% 0.0% 0.0% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 1/24 (4%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 672 525 726 (T) 567 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.452N P=0.181 P=0.228N P=0.176 P=0.724N P=1.000 |
|POLY 3 | P=0.154N P=0.250 P=0.213N P=0.306 P=0.171N P=0.426N |
|POLY 1.5 | P=0.048N* P=0.275 P=0.200N P=0.327 P=0.110N P=0.226N |
|POLY 6 | P=0.412N P=0.231 P=0.228N P=0.276 P=0.294N P=0.574N |
|LOGISTIC REGRESSION| P=0.041N* P=0.275 P=0.223N P=0.306 P=0.356N P=0.876N |
|COCH-ARM / FISHERS | P=0.003N** P=0.346 P=0.181N P=0.371 P=0.059N P=0.038N* |
|ORDER RESTRICTED | P=0.415N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 20
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Kidney: Renal Tubule |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 2/42.10 0/32.58 0/37.79 0/36.73 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 4.8% 0.0% 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 672 --- --- --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.608N P=0.339N P=0.275N P=0.348N P=0.804N P=1.000N |
|POLY 3 | P=0.234N P=0.298N P=0.262N P=0.268N P=0.378N P=0.564N |
|POLY 1.5 | P=0.239N P=0.280N P=0.252N P=0.257N P=0.310N P=0.424N |
|POLY 6 | P=0.189N P=0.317N P=0.272N P=0.288N P=0.480N P=0.651N |
|LOGISTIC REGRESSION| P=0.441N P=0.307N P=0.266N P=0.284N P=0.587N P=0.966N |
|COCH-ARM / FISHERS | P=0.188N P=0.257N P=0.248N P=0.248N P=0.248N P=0.200N |
|ORDER RESTRICTED | P=0.411N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Kidney: Transitional Epithelium |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 6/51 (12%) 6/53 (11%) 16/53 (30%) 1/53 (2%) 0/65 (0%) |
|POLY-3 RATE (b) | 4/42.25 6/34.63 6/38.96 16/40.69 1/24.51 0/9.28 |
|POLY-3 PERCENT (g) | 9.5% 17.3% 15.4% 39.3% 4.1% 0.0% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 3/24 (13%) 5/15 (33%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 672 525 443 541 548 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.202 P=0.181 P=0.295 P<0.001 ** P=0.560 P=1.000N |
|POLY 3 | P=0.530N P=0.250 P=0.317 P<0.001 ** P=0.381N P=0.426N |
|POLY 1.5 | P=0.093N P=0.275 P=0.336 P<0.001 ** P=0.281N P=0.226N |
|POLY 6 | P=0.060 P=0.231 P=0.299 P<0.001 ** P=0.536N P=0.574N |
|LOGISTIC REGRESSION| P=0.065N P=0.275 P=0.317 P=0.002 ** P=0.483N P=0.876N |
|COCH-ARM / FISHERS | P<0.001N** P=0.346 P=0.371 P=0.003 ** P=0.181N P=0.038N* |
|ORDER RESTRICTED | P=0.327N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 21
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Angiectasis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 2/53 (4%) 1/53 (2%) 3/53 (6%) 2/65 (3%) |
|POLY-3 RATE (b) | 0/41.89 1/32.58 2/37.79 1/37.16 3/25.16 2/10.57 |
|POLY-3 PERCENT (g) | 0.0% 3.1% 5.3% 2.7% 11.9% 18.9% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 2/24 (8%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) 726 (T) 604 523 243 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.408 P=0.212 P=0.468 P=0.011 * P=0.033 * |
|POLY 3 | P=0.021 * P=0.450 P=0.214 P=0.476 P=0.054 P=0.092 |
|POLY 1.5 | P=0.046 * P=0.464 P=0.223 P=0.484 P=0.077 P=0.133 |
|POLY 6 | P=0.013 * P=0.437 P=0.206 P=0.463 P=0.034 * P=0.075 |
|LOGISTIC REGRESSION| P=0.022 * P=0.408 P=0.212 P=0.515 P=0.086 P=0.300 |
|COCH-ARM / FISHERS | P=0.220 P=0.490 P=0.248 P=0.500 P=0.121 P=0.301 |
|ORDER RESTRICTED | P=0.079 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Basophilic Focus |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 27/53 (51%) 16/51 (31%) 10/53 (19%) 8/53 (15%) 4/53 (8%) 0/65 (0%) |
|POLY-3 RATE (b) | 27/45.63 16/36.90 10/38.79 8/39.71 4/26.06 0/9.28 |
|POLY-3 PERCENT (g) | 59.2% 43.4% 25.8% 20.2% 15.4% 0.0% |
|TERMINAL (d) | 16/27 (59%) 4/17 (24%) 7/24 (29%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 364 608 367 496 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.163N P=0.385N P=0.005N** P=0.015N* P=0.582 P=0.681N |
|POLY 3 | P<0.001N** P=0.106N P<0.001N** P<0.001N** P<0.001N** P=0.025N* |
|POLY 1.5 | P<0.001N** P=0.076N P<0.001N** P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.135N P=0.002N** P<0.001N** P=0.013N* P=0.321N |
|LOGISTIC REGRESSION| P<0.001N** P=0.114N P<0.001N** P<0.001N** P<0.001N** P=0.029N* |
|COCH-ARM / FISHERS | P<0.001N** P=0.034N* P<0.001N** P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.020N* (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 22
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Cholangiofibrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 2/51 (4%) 3/53 (6%) 21/53 (40%) 42/53 (79%) 29/65 (45%) |
|POLY-3 RATE (b) | 1/41.89 2/32.58 3/38.59 21/40.03 42/45.21 29/31.95 |
|POLY-3 PERCENT (g) | 2.4% 6.1% 7.8% 52.5% 92.9% 90.8% |
|TERMINAL (d) | 1/27 (4%) 2/17 (12%) 2/24 (8%) 11/15 (73%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 726 (T) 426 548 267 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.339 P=0.275 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.413 P=0.275 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.437 P=0.286 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.390 P=0.265 P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.339 P=0.296 P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.485 P=0.309 P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Clear Cell Focus |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 5/53 (9%) 1/51 (2%) 0/53 (0%) 1/53 (2%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 5/42.17 1/32.58 0/37.79 1/36.73 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 11.9% 3.1% 0.0% 2.7% 0.0% 0.0% |
|TERMINAL (d) | 4/27 (15%) 1/17 (6%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 651 726 (T) --- 726 (T) --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.449N P=0.230N P=0.045N* P=0.253N P=0.790N P=1.000N |
|POLY 3 | P=0.072N P=0.171N P=0.040N* P=0.135N P=0.117N P=0.379N |
|POLY 1.5 | P=0.056N P=0.150N P=0.036N* P=0.122N P=0.066N P=0.169N |
|POLY 6 | P=0.080N P=0.196N P=0.044N* P=0.158N P=0.233N P=0.550N |
|LOGISTIC REGRESSION| P=0.274N P=0.202N P=0.046N* P=0.187N P=0.377N P=0.931N |
|COCH-ARM / FISHERS | P=0.026N* P=0.112N P=0.028N* P=0.103N P=0.028N* P=0.016N* |
|ORDER RESTRICTED | P=0.270N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 23
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Eosinophilic Focus |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 10/53 (19%) 21/51 (41%) 23/53 (43%) 15/53 (28%) 6/53 (11%) 10/65 (15%) |
|POLY-3 RATE (b) | 10/43.62 21/39.54 23/45.27 15/43.64 6/28.39 10/18.34 |
|POLY-3 PERCENT (g) | 22.9% 53.1% 50.8% 34.4% 21.1% 54.5% |
|TERMINAL (d) | 6/27 (22%) 5/17 (29%) 8/24 (33%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 347 408 367 267 174 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.002 ** P=0.002 ** P=0.005 ** P=0.070 P=0.118 P<0.001 ** |
|POLY 3 | P=0.282N P=0.003 ** P=0.004 ** P=0.168 P=0.543N P=0.033 * |
|POLY 1.5 | P=0.057N P=0.004 ** P=0.004 ** P=0.165 P=0.374N P=0.176 |
|POLY 6 | P=0.366 P=0.003 ** P=0.005 ** P=0.167 P=0.432 P=0.007 ** |
|LOGISTIC REGRESSION| P<0.001N** P=0.006 ** P=0.006 ** P=0.213 P=0.120N P=0.333N |
|COCH-ARM / FISHERS | P<0.001N** P=0.011 * P=0.006 ** P=0.180 P=0.208N P=0.398N |
|ORDER RESTRICTED | P=0.039 * (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Fatty Change Diffuse |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 3/53 (6%) 14/51 (27%) 27/53 (51%) 45/53 (85%) 49/53 (92%) 56/65 (86%) |
|POLY-3 RATE (b) | 3/42.21 14/36.10 27/43.56 45/47.56 49/50.59 56/57.00 |
|POLY-3 PERCENT (g) | 7.1% 38.8% 62.0% 94.6% 96.9% 98.3% |
|TERMINAL (d) | 2/27 (7%) 6/17 (35%) 14/24 (58%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 639 275 408 390 267 91 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.003 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 24
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Fatty Change Focal |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 10/53 (19%) 10/51 (20%) 6/53 (11%) 1/53 (2%) 10/53 (19%) 6/65 (9%) |
|POLY-3 RATE (b) | 10/43.19 10/35.36 6/38.55 1/36.81 10/28.59 6/13.82 |
|POLY-3 PERCENT (g) | 23.2% 28.3% 15.6% 2.7% 35.0% 43.4% |
|TERMINAL (d) | 5/27 (19%) 5/17 (29%) 4/24 (17%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 586 498 572 707 383 329 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.239 P=0.312N P=0.037N* P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.109 P=0.398 P=0.279N P=0.008N** P=0.207 P=0.199 |
|POLY 1.5 | P=0.252 P=0.445 P=0.250N P=0.007N** P=0.365 P=0.522 |
|POLY 6 | P=0.049 * P=0.355 P=0.313N P=0.013N* P=0.074 P=0.080 |
|LOGISTIC REGRESSION| P=0.106 P=0.416 P=0.279N P=0.011N* P=0.258 P=0.228 |
|COCH-ARM / FISHERS | P=0.238N P=0.560 P=0.208N P=0.004N** P=0.598N P=0.106N |
|ORDER RESTRICTED | P=0.109 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Hematopoietic Cell Proliferation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 27/53 (51%) 27/51 (53%) 30/53 (57%) 32/53 (60%) 22/53 (42%) 11/65 (17%) |
|POLY-3 RATE (b) | 27/48.61 27/41.24 30/45.25 32/43.72 22/33.87 11/17.99 |
|POLY-3 PERCENT (g) | 55.6% 65.5% 66.3% 73.2% 65.0% 61.1% |
|TERMINAL (d) | 11/27 (41%) 9/17 (53%) 14/24 (58%) 13/15 (87%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 364 443 41 267 91 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.097 P=0.198 P=0.014 * P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.355 P=0.224 P=0.189 P=0.050 P=0.257 P=0.456 |
|POLY 1.5 | P=0.075N P=0.277 P=0.231 P=0.094 P=0.546 P=0.142N |
|POLY 6 | P=0.020 * P=0.197 P=0.160 P=0.019 * P=0.058 P=0.122 |
|LOGISTIC REGRESSION| P=0.015N* P=0.436 P=0.335 P=0.182 P=0.444N P=0.014N* |
|COCH-ARM / FISHERS | P<0.001N** P=0.497 P=0.349 P=0.217 P=0.218N P<0.001N** |
|ORDER RESTRICTED | P=0.399 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 25
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Hepatodiaphragmatic Nodule |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 2/51 (4%) 0/53 (0%) 2/53 (4%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 2/41.89 2/33.21 0/37.79 2/37.47 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 4.8% 6.0% 0.0% 5.3% 0.0% 0.0% |
|TERMINAL (d) | 2/27 (7%) 1/17 (6%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 525 --- 555 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.576N P=0.540 P=0.264N P=0.543 P=1.000N P=1.000N |
|POLY 3 | P=0.295N P=0.608 P=0.260N P=0.654 P=0.377N P=0.563N |
|POLY 1.5 | P=0.191N P=0.631 P=0.252N P=0.667 P=0.310N P=0.423N |
|POLY 6 | P=0.429N P=0.586 P=0.269N P=0.632 P=0.478N P=0.650N |
|LOGISTIC REGRESSION| P=0.185N P=0.613 (e) P=0.661 (e) (e) |
|COCH-ARM / FISHERS | P=0.066N P=0.676 P=0.248N P=0.691N P=0.248N P=0.200N |
|ORDER RESTRICTED | P=0.565N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 10/53 (19%) 45/53 (85%) 50/53 (94%) 61/65 (94%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 10/39.24 45/47.09 50/50.87 61/61.04 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 25.5% 95.6% 98.3% 99.9% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 7/24 (29%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 474 480 267 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 26
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 49/53 (92%) 47/51 (92%) 50/53 (94%) 52/53 (98%) 51/53 (96%) 64/65 (98%) |
|POLY-3 RATE (b) | 49/51.05 47/49.76 50/51.37 52/53.00 51/51.92 64/64.15 |
|POLY-3 PERCENT (g) | 96.0% 94.5% 97.3% 98.1% 98.2% 99.8% |
|TERMINAL (d) | 26/27 (96%) 15/17 (88%) 24/24 (100%) 14/15 (93%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 313 70 399 41 166 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.030 * P=0.190 P=0.007 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.050 P=0.546N P=0.578 P=0.473 P=0.455 P=0.171 |
|POLY 1.5 | P=0.056 P=0.569N P=0.504 P=0.345 P=0.427 P=0.137 |
|POLY 6 | P=0.053 P=0.516N P=0.649 P=0.619 P=0.466 P=0.265 |
|LOGISTIC REGRESSION| P=0.020 * P=0.583 P=0.351 P=0.133 P=0.176 P=0.054 |
|COCH-ARM / FISHERS | P=0.061 P=0.620N P=0.500 P=0.181 P=0.339 P=0.125 |
|ORDER RESTRICTED | P=0.056 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Metaplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 4/53 (8%) 4/65 (6%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 4/26.18 4/11.99 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 15.3% 33.4% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- 447 338 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) (e) P=0.016 * P<0.001 ** |
|POLY 3 | P<0.001 ** (e) (e) (e) P=0.021 * P=0.009 ** |
|POLY 1.5 | P<0.001 ** (e) (e) (e) P=0.034 * P=0.018 * |
|POLY 6 | P<0.001 ** (e) (e) (e) P=0.011 * P=0.006 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) (e) (e) P=0.096 P=0.014 * |
|COCH-ARM / FISHERS | P<0.001 ** (e) (e) (e) P=0.059 P=0.088 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 27
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Mixed Cell Focus |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 38/53 (72%) 28/51 (55%) 32/53 (60%) 16/53 (30%) 2/53 (4%) 3/65 (5%) |
|POLY-3 RATE (b) | 38/45.68 28/38.34 32/44.02 16/38.41 2/24.80 3/11.13 |
|POLY-3 PERCENT (g) | 83.2% 73.0% 72.7% 41.7% 8.1% 27.0% |
|TERMINAL (d) | 26/27 (96%) 15/17 (88%) 20/24 (83%) 10/15 (67%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 443 408 534 482 429 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.368N P=0.319 P=0.452N P=0.035N* P=0.388N P=0.005 ** |
|POLY 3 | P<0.001N** P=0.161N P=0.140N P<0.001N** P<0.001N** P<0.001N** |
|POLY 1.5 | P<0.001N** P=0.127N P=0.146N P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.181N P=0.135N P<0.001N** P<0.001N** P=0.254N |
|LOGISTIC REGRESSION| P<0.001N** P=0.419N P=0.346N P<0.001N** P<0.001N** P=0.587N |
|COCH-ARM / FISHERS | P<0.001N** P=0.057N P=0.153N P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Necrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 3/53 (6%) 13/51 (25%) 6/53 (11%) 26/53 (49%) 17/53 (32%) 27/65 (42%) |
|POLY-3 RATE (b) | 3/42.94 13/38.42 6/40.55 26/46.15 17/33.43 27/31.21 |
|POLY-3 PERCENT (g) | 7.0% 33.8% 14.8% 56.3% 50.9% 86.5% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 0/24 (0%) 4/15 (27%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 564 347 408 78 313 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.002 ** P=0.192 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.002 ** P=0.212 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.002 ** P=0.223 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.002 ** P=0.204 P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P=0.003 ** P=0.010 * P=0.291 P<0.001 ** P=0.003 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.005 ** P=0.244 P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 28
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Pigmentation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 5/53 (9%) 18/51 (35%) 38/53 (72%) 52/53 (98%) 53/53 (100%) 60/65 (92%) |
|POLY-3 RATE (b) | 5/43.23 18/37.02 38/46.33 52/52.00 53/53.00 60/60.56 |
|POLY-3 PERCENT (g) | 11.6% 48.6% 82.0% 100.0% 100.0% 99.1% |
|TERMINAL (d) | 2/27 (7%) 8/17 (47%) 20/24 (83%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 328 408 78 166 91 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver |
| Toxic Hepatopathy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 8/51 (16%) 32/53 (60%) 51/53 (96%) 52/53 (98%) 64/65 (98%) |
|POLY-3 RATE (b) | 0/41.89 8/34.02 32/44.65 51/51.00 52/52.01 64/64.00 |
|POLY-3 PERCENT (g) | 0.0% 23.5% 71.7% 100.0% 100.0% 100.0% |
|TERMINAL (d) | 0/27 (0%) 4/17 (24%) 18/24 (75%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 484 408 261 267 91 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.002 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.002 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 29
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Bile Duct |
| Cyst |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 3/51 (6%) 3/53 (6%) 14/53 (26%) 25/53 (47%) 14/65 (22%) |
|POLY-3 RATE (b) | 4/42.10 3/33.78 3/37.79 14/37.69 25/34.09 14/19.17 |
|POLY-3 PERCENT (g) | 9.5% 8.9% 7.9% 37.1% 73.4% 73.0% |
|TERMINAL (d) | 3/27 (11%) 0/17 (0%) 3/24 (13%) 8/15 (53%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 672 525 726 (T) 636 447 289 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.600 P=0.571N P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.619N P=0.559N P=0.002 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.590N P=0.537N P=0.004 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.643N P=0.583N P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.608N P=0.581N P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.522N P=0.500N P=0.009 ** P<0.001 ** P=0.030 * |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Bile Duct |
| Fibrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 6/53 (11%) 2/51 (4%) 3/53 (6%) 10/53 (19%) 3/53 (6%) 4/65 (6%) |
|POLY-3 RATE (b) | 6/42.12 2/32.58 3/38.68 10/39.53 3/25.25 4/12.37 |
|POLY-3 PERCENT (g) | 14.2% 6.1% 7.8% 25.3% 11.9% 32.3% |
|TERMINAL (d) | 5/27 (19%) 2/17 (12%) 1/24 (4%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 665 726 (T) 586 537 482 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.322N P=0.320N P=0.063 P=0.050 P=0.004 ** |
|POLY 3 | P=0.132 P=0.230N P=0.284N P=0.161 P=0.535N P=0.229 |
|POLY 1.5 | P=0.334 P=0.200N P=0.269N P=0.172 P=0.396N P=0.489 |
|POLY 6 | P=0.030 * P=0.264N P=0.295N P=0.147 P=0.544 P=0.115 |
|LOGISTIC REGRESSION| P=0.172 P=0.285N P=0.299N P=0.148 P=0.576 P=0.362 |
|COCH-ARM / FISHERS | P=0.251N P=0.148N P=0.244N P=0.208 P=0.244N P=0.251N |
|ORDER RESTRICTED | P=0.141 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 30
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Bile Duct |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 5/53 (9%) 5/51 (10%) 7/53 (13%) 46/53 (87%) 52/53 (98%) 60/65 (92%) |
|POLY-3 RATE (b) | 5/42.04 5/32.90 7/38.20 46/48.29 52/52.01 60/60.13 |
|POLY-3 PERCENT (g) | 11.9% 15.2% 18.3% 95.3% 100.0% 99.8% |
|TERMINAL (d) | 4/27 (15%) 4/17 (24%) 6/24 (25%) 14/15 (93%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 687 639 608 367 267 174 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.339 P=0.290 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.470 P=0.310 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.514 P=0.336 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.427 P=0.287 P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.387 P=0.273 P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.605 P=0.380 P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Centrilobular |
| Degeneration |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 3/51 (6%) 8/53 (15%) 8/53 (15%) 3/53 (6%) 8/65 (12%) |
|POLY-3 RATE (b) | 2/42.71 3/34.67 8/41.87 8/39.66 3/26.01 8/16.92 |
|POLY-3 PERCENT (g) | 4.7% 8.7% 19.1% 20.2% 11.5% 47.3% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 564 436 399 367 313 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.384 P=0.040 * P=0.030 * P=0.243 P=0.006 ** |
|POLY 3 | P=0.017 * P=0.406 P=0.040 * P=0.032 * P=0.291 P<0.001 ** |
|POLY 1.5 | P=0.063 P=0.429 P=0.042 * P=0.036 * P=0.381 P=0.006 ** |
|POLY 6 | P=0.002 ** P=0.383 P=0.040 * P=0.027 * P=0.187 P<0.001 ** |
|LOGISTIC REGRESSION| P=0.171N P=0.623 P=0.072 P=0.056 P=0.652N P=0.493N |
|COCH-ARM / FISHERS | P=0.340 P=0.482 P=0.046 * P=0.046 * P=0.500 P=0.091 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 31
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Centrilobular |
| Fibrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 7/53 (13%) 36/53 (68%) 52/53 (98%) 57/65 (88%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 7/40.39 36/46.63 52/52.01 57/59.02 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 17.3% 77.2% 100.0% 96.6% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 3/24 (13%) 8/15 (53%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 408 367 267 174 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.008 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P=0.006 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.007 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.006 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.012 * P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.006 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Hepatocyte |
| Glandular Structures |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 1/53 (2%) 5/53 (9%) 25/65 (38%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 1/37.09 5/26.22 25/31.26 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 2.7% 19.1% 80.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 628 450 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) P=0.462 P=0.002 ** P<0.001 ** |
|POLY 3 | P<0.001 ** (e) (e) P=0.476 P=0.008 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) (e) P=0.484 P=0.014 * P<0.001 ** |
|POLY 6 | P<0.001 ** (e) (e) P=0.462 P=0.003 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) (e) P=0.504 P=0.027 * P=0.007 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) (e) P=0.500 P=0.028 * P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 32
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Hepatocyte |
| Hypertrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 16/51 (31%) 22/53 (42%) 47/53 (89%) 52/53 (98%) 65/65 (100%) |
|POLY-3 RATE (b) | 0/41.89 16/37.84 22/43.78 47/48.93 52/52.01 65/65.00 |
|POLY-3 PERCENT (g) | 0.0% 42.3% 50.3% 96.1% 100.0% 100.0% |
|TERMINAL (d) | 0/27 (0%) 4/17 (24%) 9/24 (38%) 14/15 (93%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 400 443 367 267 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Hepatocyte |
| Multinucleated |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 9/51 (18%) 21/53 (40%) 48/53 (91%) 52/53 (98%) 48/65 (74%) |
|POLY-3 RATE (b) | 0/41.89 9/33.70 21/42.85 48/50.29 52/52.80 48/50.32 |
|POLY-3 PERCENT (g) | 0.0% 26.7% 49.0% 95.4% 98.5% 95.4% |
|TERMINAL (d) | 0/27 (0%) 6/17 (35%) 10/24 (42%) 14/15 (93%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 484 408 261 166 91 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 33
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Oval Cell |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 4/51 (8%) 23/53 (43%) 49/53 (92%) 52/53 (98%) 62/65 (95%) |
|POLY-3 RATE (b) | 4/41.89 4/33.76 23/41.82 49/49.34 52/52.01 62/62.03 |
|POLY-3 PERCENT (g) | 9.6% 11.9% 55.0% 99.3% 100.0% 100.0% |
|TERMINAL (d) | 4/27 (15%) 2/17 (12%) 14/24 (58%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 374 455 367 267 174 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.412 P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.521 P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.552 P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.491 P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.525 P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.620 P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Portal |
| Fibrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 2/53 (4%) 37/53 (70%) 52/53 (98%) 58/65 (89%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 2/38.51 37/45.40 52/52.01 58/58.27 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 5.2% 81.5% 100.0% 99.5% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 1/24 (4%) 10/15 (67%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 474 480 267 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.216 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P=0.218 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.225 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.212 P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.253 P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.248 P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 34
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Liver: Serosa |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 2/51 (4%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 0/41.89 2/33.29 0/37.79 0/36.73 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 0.0% 6.0% 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 525 --- --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.499N P=0.169 (e) (e) (e) (e) |
|POLY 3 | P=0.365N P=0.189 (e) (e) (e) (e) |
|POLY 1.5 | P=0.329N P=0.201 (e) (e) (e) (e) |
|POLY 6 | P=0.361N P=0.179 (e) (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.238N P=0.228 (e) (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.208N P=0.238 (e) (e) (e) (e) |
|ORDER RESTRICTED | P=0.607N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lung |
| Congestion |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 2/53 (4%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 2/38.58 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.2% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 41 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.516N (e) (e) P=0.238 (e) (e) |
|POLY 3 | P=0.439 (e) (e) P=0.219 (e) (e) |
|POLY 1.5 | P=0.641 (e) (e) P=0.227 (e) (e) |
|POLY 6 | P=0.177 (e) (e) P=0.205 (e) (e) |
|LOGISTIC REGRESSION| P=0.164N (e) (e) P=0.558 (e) (e) |
|COCH-ARM / FISHERS | P=0.438N (e) (e) P=0.248 (e) (e) |
|ORDER RESTRICTED | P=0.594 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 35
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lung |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 1/53 (2%) 2/53 (4%) 4/66 (6%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 1/37.73 2/25.26 4/12.86 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 2.7% 7.9% 31.1% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 41 397 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) P=0.500 P=0.142 P=0.016 * |
|POLY 3 | P<0.001 ** (e) (e) P=0.479 P=0.146 P=0.009 ** |
|POLY 1.5 | P<0.001 ** (e) (e) P=0.488 P=0.182 P=0.019 * |
|POLY 6 | P<0.001 ** (e) (e) P=0.465 P=0.109 P=0.006 ** |
|LOGISTIC REGRESSION| P=0.129 (e) (e) (e) P=0.371 P=0.397 |
|COCH-ARM / FISHERS | P=0.003 ** (e) (e) P=0.500 P=0.248 P=0.091 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lung |
| Infiltration Cellular Histiocyte |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 40/53 (75%) 33/51 (65%) 46/53 (87%) 48/53 (91%) 46/53 (87%) 33/66 (50%) |
|POLY-3 RATE (b) | 40/49.03 33/40.13 46/48.47 48/49.70 46/48.95 33/37.16 |
|POLY-3 PERCENT (g) | 81.6% 82.2% 94.9% 96.6% 94.0% 88.8% |
|TERMINAL (d) | 21/27 (78%) 15/17 (88%) 24/24 (100%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 362 374 408 261 267 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.174 P=0.060 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.134 P=0.584 P=0.027 * P=0.011 * P=0.040 * P=0.245 |
|POLY 1.5 | P=0.450N P=0.469N P=0.042 * P=0.011 * P=0.062 P=0.456N |
|POLY 6 | P=0.019 * P=0.426 P=0.019 * P=0.009 ** P=0.019 * P=0.064 |
|LOGISTIC REGRESSION| P=0.090 P=0.542N P=0.037 * P=0.008 ** P=0.035 * P=0.519 |
|COCH-ARM / FISHERS | P<0.001N** P=0.162N P=0.107 P=0.034 * P=0.107 P=0.004N** |
|ORDER RESTRICTED | P=0.019 * (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 36
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lung |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 5/53 (9%) 9/51 (18%) 7/53 (13%) 3/53 (6%) 2/53 (4%) 2/66 (3%) |
|POLY-3 RATE (b) | 5/43.02 9/35.07 7/38.67 3/38.32 2/25.16 2/11.03 |
|POLY-3 PERCENT (g) | 11.6% 25.7% 18.1% 7.8% 8.0% 18.1% |
|TERMINAL (d) | 3/27 (11%) 3/17 (18%) 5/24 (21%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 70 523 539 504 243 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.215 P=0.062 P=0.297 P=0.512N P=0.502 P=0.162 |
|POLY 3 | P=0.164N P=0.093 P=0.304 P=0.421N P=0.474N P=0.481 |
|POLY 1.5 | P=0.076N P=0.116 P=0.332 P=0.399N P=0.350N P=0.545N |
|POLY 6 | P=0.269N P=0.077 P=0.277 P=0.456N P=0.646 P=0.315 |
|LOGISTIC REGRESSION| P=0.021N* P=0.163 P=0.327 P=0.335N P=0.275N P=0.471N |
|COCH-ARM / FISHERS | P=0.005N** P=0.174 P=0.380 P=0.358N P=0.219N P=0.140N |
|ORDER RESTRICTED | P=0.579N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lung |
| Metaplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 2/53 (4%) 14/53 (26%) 16/53 (30%) 7/66 (11%) |
|POLY-3 RATE (b) | 0/41.89 1/32.58 2/38.20 14/37.93 16/31.82 7/14.88 |
|POLY-3 PERCENT (g) | 0.0% 3.1% 5.2% 36.9% 50.3% 47.1% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 1/24 (4%) 10/15 (67%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) 608 567 313 289 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.408 P=0.207 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.450 P=0.217 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.464 P=0.224 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.437 P=0.210 P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.408 P=0.224 P<0.001 ** P<0.001 ** P=0.019 * |
|COCH-ARM / FISHERS | P=0.007 ** P=0.490 P=0.248 P<0.001 ** P<0.001 ** P=0.014 * |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 37
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lung: Alveolar Epithelium |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 18/53 (34%) 10/51 (20%) 2/53 (4%) 1/53 (2%) 1/53 (2%) 4/66 (6%) |
|POLY-3 RATE (b) | 18/43.48 10/33.86 2/37.79 1/36.73 1/24.56 4/12.41 |
|POLY-3 PERCENT (g) | 41.4% 29.5% 5.3% 2.7% 4.1% 32.2% |
|TERMINAL (d) | 13/27 (48%) 7/17 (41%) 2/24 (8%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 443 726 (T) 726 (T) 525 303 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.037 * P=0.394N P<0.001N** P<0.001N** P=0.487N P=0.002 ** |
|POLY 3 | P=0.003N** P=0.197N P<0.001N** P<0.001N** P<0.001N** P=0.426N |
|POLY 1.5 | P=0.002N** P=0.147N P<0.001N** P<0.001N** P<0.001N** P=0.064N |
|POLY 6 | P=0.003N** P=0.265N P<0.001N** P<0.001N** P=0.021N* P=0.408 |
|LOGISTIC REGRESSION| P=0.204N P=0.244N P<0.001N** P<0.001N** P=0.012N* P=0.586 |
|COCH-ARM / FISHERS | P<0.001N** P=0.076N P<0.001N** P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.033N* (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lung: Alveolar Epithelium |
| Metaplasia Bronchiolar |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 14/51 (27%) 39/53 (74%) 46/53 (87%) 35/53 (66%) 8/66 (12%) |
|POLY-3 RATE (b) | 1/41.89 14/35.34 39/46.42 46/47.90 35/41.87 8/16.09 |
|POLY-3 PERCENT (g) | 2.4% 39.6% 84.0% 96.0% 83.6% 49.7% |
|TERMINAL (d) | 1/27 (4%) 7/17 (41%) 21/24 (88%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 498 408 367 267 267 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P=0.002 ** |
|POLY 6 | P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P=0.030 * P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P=0.066 |
|COCH-ARM / FISHERS | P=0.011N* P<0.001 ** P<0.001 ** P<0.001 ** P<0.001 ** P=0.035 * |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 38
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lung: Serosa |
| Fibrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 3/53 (6%) 0/51 (0%) 0/53 (0%) 1/53 (2%) 16/53 (30%) 8/66 (12%) |
|POLY-3 RATE (b) | 3/42.18 0/32.58 0/37.79 1/36.96 16/32.54 8/15.93 |
|POLY-3 PERCENT (g) | 7.1% 0.0% 0.0% 2.7% 49.2% 50.2% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 649 --- --- 667 349 294 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.208N P=0.148N P=0.460N P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.171N P=0.139N P=0.353N P<0.001 ** P=0.003 ** |
|POLY 1.5 | P<0.001 ** P=0.155N P=0.131N P=0.336N P<0.001 ** P=0.014 * |
|POLY 6 | P<0.001 ** P=0.189N P=0.147N P=0.382N P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.180N P=0.144N P=0.370N P<0.001 ** P=0.084 |
|COCH-ARM / FISHERS | P<0.001 ** P=0.129N P=0.121N P=0.309N P<0.001 ** P=0.188 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node, Mandibular |
| Ectasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 3/53 (6%) 2/51 (4%) 3/53 (6%) 4/52 (8%) 4/52 (8%) 1/66 (2%) |
|POLY-3 RATE (b) | 3/42.29 2/33.39 3/37.79 4/36.92 4/25.87 1/10.25 |
|POLY-3 PERCENT (g) | 7.1% 6.0% 7.9% 10.8% 15.5% 9.8% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 3/24 (13%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 639 567 726 (T) 602 383 313 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.666N P=0.597 P=0.290 P=0.029 * P=0.427 |
|POLY 3 | P=0.145 P=0.606N P=0.610 P=0.426 P=0.254 P=0.594 |
|POLY 1.5 | P=0.364 P=0.579N P=0.630 P=0.448 P=0.355 P=0.565N |
|POLY 6 | P=0.048 * P=0.631N P=0.588 P=0.390 P=0.146 P=0.452 |
|LOGISTIC REGRESSION| P=0.325 P=0.575N P=0.596 P=0.410 P=0.395 P=0.723N |
|COCH-ARM / FISHERS | P=0.221N P=0.518N P=0.661N P=0.489 P=0.489 P=0.232N |
|ORDER RESTRICTED | P=0.589 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 39
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node, Mandibular |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 1/53 (2%) 0/52 (0%) 2/52 (4%) 7/66 (11%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 1/37.79 0/36.34 2/25.70 7/15.76 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 2.7% 0.0% 7.8% 44.4% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 726 (T) --- 313 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.477 (e) P=0.231 P=0.004 ** |
|POLY 3 | P<0.001 ** (e) P=0.479 (e) P=0.148 P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.487 (e) P=0.183 P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.472 (e) P=0.109 P<0.001 ** |
|LOGISTIC REGRESSION| P=0.027 * (e) P=0.477 (e) P=0.377 P=0.363 |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.500 (e) P=0.243 P=0.014 * |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node, Mandibular |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 45/53 (85%) 35/51 (69%) 34/53 (64%) 27/52 (52%) 22/52 (42%) 20/66 (30%) |
|POLY-3 RATE (b) | 45/51.67 35/41.98 34/46.81 27/43.88 22/36.54 20/26.79 |
|POLY-3 PERCENT (g) | 87.1% 83.4% 72.6% 61.5% 60.2% 74.7% |
|TERMINAL (d) | 24/27 (89%) 15/17 (88%) 17/24 (71%) 7/15 (47%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 70 408 261 337 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.288 P=0.226N P=0.265N P=0.006 ** P<0.001 ** |
|POLY 3 | P=0.010N* P=0.409N P=0.049N* P=0.002N** P<0.001N** P=0.122N |
|POLY 1.5 | P<0.001N** P=0.227N P=0.032N* P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P=0.158N P=0.579N P=0.073N P=0.004N** P=0.026N* P=0.546 |
|LOGISTIC REGRESSION| P<0.001N** P=0.114N P=0.016N* P<0.001N** P<0.001N** P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.041N* P=0.012N* P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.019N* (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 40
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node, Mandibular |
| Hyperplasia Lymphoid |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 3/53 (6%) 0/52 (0%) 2/52 (4%) 1/66 (2%) |
|POLY-3 RATE (b) | 0/41.89 1/32.58 3/38.56 0/36.34 2/24.19 1/10.31 |
|POLY-3 PERCENT (g) | 0.0% 3.1% 7.8% 0.0% 8.3% 9.7% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 2/24 (8%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) 443 --- 674 174 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.007 ** P=0.408 P=0.108 (e) P=0.002 ** P=0.538 |
|POLY 3 | P=0.195 P=0.450 P=0.104 (e) P=0.140 P=0.308 |
|POLY 1.5 | P=0.290 P=0.464 P=0.109 (e) P=0.177 P=0.380 |
|POLY 6 | P=0.150 P=0.437 P=0.099 (e) P=0.102 P=0.268 |
|LOGISTIC REGRESSION| P=0.360 P=0.408 P=0.122 (e) P=0.016 * (e) |
|COCH-ARM / FISHERS | P=0.576 P=0.490 P=0.121 (e) P=0.243 P=0.555 |
|ORDER RESTRICTED | P=0.320 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node, Mesenteric |
| Ectasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 1/51 (2%) 0/53 (0%) 2/53 (4%) 1/52 (2%) 2/65 (3%) |
|POLY-3 RATE (b) | 1/41.89 1/32.58 0/37.79 2/37.58 1/24.16 2/11.14 |
|POLY-3 PERCENT (g) | 2.4% 3.1% 0.0% 5.3% 4.1% 18.0% |
|TERMINAL (d) | 1/27 (4%) 1/17 (6%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 726 (T) --- 567 530 245 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.003 ** P=0.656 P=0.523N P=0.400 P=0.402 P=0.183 |
|POLY 3 | P=0.138 P=0.702 P=0.521N P=0.462 P=0.626 P=0.193 |
|POLY 1.5 | P=0.175 P=0.719 P=0.513N P=0.475 P=0.688 P=0.298 |
|POLY 6 | P=0.105 P=0.685 P=0.528N P=0.442 P=0.533 P=0.142 |
|LOGISTIC REGRESSION| P=0.352 P=0.656 (e) P=0.493 P=0.726 P=0.813 |
|COCH-ARM / FISHERS | P=0.330 P=0.743 P=0.500N P=0.500 P=0.748 P=0.577 |
|ORDER RESTRICTED | P=0.078 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 41
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node, Mesenteric |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 2/51 (4%) 2/53 (4%) 2/53 (4%) 4/52 (8%) 14/65 (22%) |
|POLY-3 RATE (b) | 0/41.89 2/32.67 2/38.31 2/37.59 4/26.33 14/22.13 |
|POLY-3 PERCENT (g) | 0.0% 6.1% 5.2% 5.3% 15.2% 63.3% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 1/24 (4%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 705 567 537 313 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.149 P=0.214 P=0.220 P=0.022 * P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.186 P=0.217 P=0.213 P=0.021 * P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.199 P=0.224 P=0.221 P=0.034 * P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.174 P=0.211 P=0.201 P=0.011 * P<0.001 ** |
|LOGISTIC REGRESSION| P=0.004 ** P=0.157 P=0.233 P=0.254 P=0.188 P=0.136 |
|COCH-ARM / FISHERS | P<0.001 ** P=0.238 P=0.248 P=0.248 P=0.057 P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node, Mesenteric |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 3/53 (6%) 0/51 (0%) 1/53 (2%) 6/53 (11%) 5/52 (10%) 0/65 (0%) |
|POLY-3 RATE (b) | 3/42.49 0/32.58 1/38.20 6/38.25 5/26.76 0/9.28 |
|POLY-3 PERCENT (g) | 7.1% 0.0% 2.6% 15.7% 18.7% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 639 --- 608 565 337 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.002 ** P=0.201N P=0.371N P=0.137 P=0.048 * P=1.000N |
|POLY 3 | P=0.016 * P=0.173N P=0.344N P=0.190 P=0.147 P=0.486N |
|POLY 1.5 | P=0.137 P=0.156N P=0.329N P=0.207 P=0.223 P=0.307N |
|POLY 6 | P<0.001 ** P=0.192N P=0.359N P=0.166 P=0.076 P=0.606N |
|LOGISTIC REGRESSION| P=0.464 P=0.156N P=0.315N P=0.209 P=0.458 P=0.661N |
|COCH-ARM / FISHERS | P=0.332N P=0.129N P=0.309N P=0.244 P=0.347 P=0.088N |
|ORDER RESTRICTED | P=0.451 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 42
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node: Mediastinal |
| Ectasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 7/28 (25%) 7/16 (44%) 7/16 (44%) 7/25 (28%) 7/20 (35%) 27/45 (60%) |
|POLY-3 RATE (b) | 7/23.39 7/13.62 7/13.19 7/18.37 7/13.66 27/29.76 |
|POLY-3 PERCENT (g) | 29.9% 51.4% 53.1% 38.1% 51.3% 90.7% |
|TERMINAL (d) | 2/12 (17%) 1/4 (25%) 3/7 (43%) 0/5 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 275 443 534 313 91 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.279 P=0.402 P=0.369 P=0.021 * P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.166 P=0.147 P=0.411 P=0.172 P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.169 P=0.145 P=0.460 P=0.238 P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.164 P=0.153 P=0.347 P=0.101 P<0.001 ** |
|LOGISTIC REGRESSION| P=0.104 P=0.215 P=0.181 P=0.532 P=0.468 P=0.140 |
|COCH-ARM / FISHERS | P=0.004 ** P=0.171 P=0.171 P=0.525 P=0.332 P=0.003 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node: Mediastinal |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/28 (7%) 2/16 (13%) 4/16 (25%) 15/25 (60%) 7/20 (35%) 25/45 (56%) |
|POLY-3 RATE (b) | 2/21.96 2/10.73 4/11.85 15/21.55 7/14.28 25/28.50 |
|POLY-3 PERCENT (g) | 9.1% 18.6% 33.8% 69.6% 49.0% 87.7% |
|TERMINAL (d) | 0/12 (0%) 1/4 (25%) 2/7 (29%) 2/5 (40%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 586 651 567 261 313 174 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.497 P=0.215 P<0.001 ** P=0.008 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.419 P=0.090 P<0.001 ** P=0.006 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.445 P=0.095 P<0.001 ** P=0.010 * P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.385 P=0.087 P<0.001 ** P=0.002 ** P<0.001 ** |
|LOGISTIC REGRESSION| P=0.017 * P=0.450 P=0.103 P<0.001 ** P=0.060 P=0.042 * |
|COCH-ARM / FISHERS | P<0.001 ** P=0.463 P=0.116 P<0.001 ** P=0.020 * P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 43
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node: Mediastinal |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/28 (0%) 3/16 (19%) 0/16 (0%) 3/25 (12%) 2/20 (10%) 2/45 (4%) |
|POLY-3 RATE (b) | 0/21.26 3/11.72 0/10.91 3/17.31 2/10.58 2/7.29 |
|POLY-3 PERCENT (g) | 0.0% 25.6% 0.0% 17.3% 18.9% 27.4% |
|TERMINAL (d) | 0/12 (0%) 0/4 (0%) 0/7 (0%) 0/5 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 525 --- 570 555 611 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.075 (e) P=0.101 P=0.064 P<0.001 ** |
|POLY 3 | P=0.102 P=0.028 * (e) P=0.077 P=0.105 P=0.108 |
|POLY 1.5 | P=0.232 P=0.030 * (e) P=0.085 P=0.128 P=0.165 |
|POLY 6 | P=0.046 * P=0.027 * (e) P=0.065 P=0.080 P=0.083 |
|LOGISTIC REGRESSION| P=0.165 P=0.044 * (e) P=0.102 P=0.150 P=0.004 ** |
|COCH-ARM / FISHERS | P=0.451N P=0.042 * (e) P=0.098 P=0.168 P=0.377 |
|ORDER RESTRICTED | P=0.086 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node: Mediastinal |
| Hyperplasia Lymphoid |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/28 (0%) 0/16 (0%) 2/16 (13%) 0/25 (0%) 0/20 (0%) 0/45 (0%) |
|POLY-3 RATE (b) | 0/21.26 0/10.45 2/11.58 0/16.09 0/9.74 0/6.56 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 17.3% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/12 (0%) 0/4 (0%) 1/7 (14%) 0/5 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 504 --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.629N (e) P=0.171 (e) (e) (e) |
|POLY 3 | P=0.452N (e) P=0.108 (e) (e) (e) |
|POLY 1.5 | P=0.349N (e) P=0.110 (e) (e) (e) |
|POLY 6 | P=0.545N (e) P=0.106 (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.273N (e) P=0.124 (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.188N (e) P=0.127 (e) (e) (e) |
|ORDER RESTRICTED | P=0.551N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 44
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node: Mediastinal |
| Pigmentation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/28 (0%) 0/16 (0%) 0/16 (0%) 0/25 (0%) 0/20 (0%) 2/45 (4%) |
|POLY-3 RATE (b) | 0/21.26 0/10.45 0/10.91 0/16.09 0/9.74 2/8.07 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 0.0% 24.8% |
|TERMINAL (d) | 0/12 (0%) 0/4 (0%) 0/7 (0%) 0/5 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- --- 289 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) (e) (e) P=0.036 * |
|POLY 3 | P=0.120 (e) (e) (e) (e) P=0.114 |
|POLY 1.5 | P=0.068 (e) (e) (e) (e) P=0.171 |
|POLY 6 | P=0.169 (e) (e) (e) (e) P=0.087 |
|LOGISTIC REGRESSION| P=0.102 (e) (e) (e) (e) P=0.394 |
|COCH-ARM / FISHERS | P=0.053 (e) (e) (e) (e) P=0.377 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node: Pancreatic |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/28 (0%) 0/16 (0%) 0/16 (0%) 0/25 (0%) 1/20 (5%) 4/45 (9%) |
|POLY-3 RATE (b) | 0/21.26 0/10.45 0/10.91 0/16.09 1/10.50 4/10.12 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 9.5% 39.5% |
|TERMINAL (d) | 0/12 (0%) 0/4 (0%) 0/7 (0%) 0/5 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- 450 243 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) (e) P=0.470 P=0.020 * |
|POLY 3 | P=0.003 ** (e) (e) (e) P=0.365 P=0.013 * |
|POLY 1.5 | P=0.002 ** (e) (e) (e) P=0.396 P=0.031 * |
|POLY 6 | P=0.002 ** (e) (e) (e) P=0.323 P=0.007 ** |
|LOGISTIC REGRESSION| P=0.095 (e) (e) (e) P=0.515 P=0.412 |
|COCH-ARM / FISHERS | P=0.007 ** (e) (e) (e) P=0.417 P=0.137 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 45
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node: Pancreatic |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/28 (0%) 0/16 (0%) 0/16 (0%) 1/25 (4%) 4/20 (20%) 3/45 (7%) |
|POLY-3 RATE (b) | 0/21.26 0/10.45 0/10.91 1/16.37 4/11.19 3/8.86 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 6.1% 35.7% 33.9% |
|TERMINAL (d) | 0/12 (0%) 0/4 (0%) 0/7 (0%) 0/5 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 651 450 342 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) P=0.476 P<0.001 ** P=0.004 ** |
|POLY 3 | P<0.001 ** (e) (e) P=0.448 P=0.007 ** P=0.038 * |
|POLY 1.5 | P<0.001 ** (e) (e) P=0.463 P=0.011 * P=0.070 |
|POLY 6 | P<0.001 ** (e) (e) P=0.423 P=0.003 ** P=0.025 * |
|LOGISTIC REGRESSION| P=0.002 ** (e) (e) P=0.462 P=0.016 * P=0.158 |
|COCH-ARM / FISHERS | P=0.040 * (e) (e) P=0.472 P=0.025 * P=0.228 |
|ORDER RESTRICTED | P=0.005 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node: Pancreatic |
| Hyperplasia Lymphoid |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/28 (0%) 0/16 (0%) 0/16 (0%) 2/25 (8%) 0/20 (0%) 1/45 (2%) |
|POLY-3 RATE (b) | 0/21.26 0/10.45 0/10.91 2/16.57 0/9.74 1/7.49 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 12.1% 0.0% 13.4% |
|TERMINAL (d) | 0/12 (0%) 0/4 (0%) 0/7 (0%) 0/5 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 662 --- 289 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.046 * (e) (e) P=0.179 (e) P=0.457 |
|POLY 3 | P=0.283 (e) (e) P=0.180 (e) P=0.342 |
|POLY 1.5 | P=0.365 (e) (e) P=0.194 (e) P=0.427 |
|POLY 6 | P=0.170 (e) (e) P=0.158 (e) P=0.291 |
|LOGISTIC REGRESSION| P=0.505 (e) (e) P=0.179 (e) P=0.934 |
|COCH-ARM / FISHERS | P=0.536 (e) (e) P=0.218 (e) P=0.616 |
|ORDER RESTRICTED | P=0.143 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 46
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Lymph Node: Renal |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/28 (0%) 0/16 (0%) 0/16 (0%) 0/25 (0%) 2/20 (10%) 2/45 (4%) |
|POLY-3 RATE (b) | 0/21.26 0/10.45 0/10.91 0/16.09 2/10.45 2/7.54 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 19.1% 26.5% |
|TERMINAL (d) | 0/12 (0%) 0/4 (0%) 0/7 (0%) 0/5 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- 623 545 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) (e) P=0.064 P<0.001 ** |
|POLY 3 | P=0.005 ** (e) (e) (e) P=0.103 P=0.110 |
|POLY 1.5 | P=0.009 ** (e) (e) (e) P=0.127 P=0.166 |
|POLY 6 | P=0.004 ** (e) (e) (e) P=0.078 P=0.085 |
|LOGISTIC REGRESSION| P<0.001 ** (e) (e) (e) P=0.115 P=0.028 * |
|COCH-ARM / FISHERS | P=0.057 (e) (e) (e) P=0.168 P=0.377 |
|ORDER RESTRICTED | P=0.010 * (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Cyst |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 2/51 (4%) 2/53 (4%) 2/53 (4%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 1/42.21 2/33.25 2/38.83 2/36.89 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 2.4% 6.0% 5.2% 5.4% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 639 541 523 686 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.473N P=0.376 P=0.440 P=0.368 P=0.713N P=1.000N |
|POLY 3 | P=0.320N P=0.418 P=0.471 P=0.453 P=0.605N P=0.697N |
|POLY 1.5 | P=0.189N P=0.439 P=0.481 P=0.470 P=0.559N P=0.626N |
|POLY 6 | P=0.505N P=0.397 P=0.462 P=0.426 P=0.664N P=0.735N |
|LOGISTIC REGRESSION| P=0.103N P=0.479 P=0.537 P=0.449 P=0.593N P=0.905N |
|COCH-ARM / FISHERS | P=0.052N P=0.485 P=0.500 P=0.500 P=0.500N P=0.445N |
|ORDER RESTRICTED | P=0.621N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 47
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 26/53 (49%) 17/51 (33%) 13/53 (25%) 6/53 (11%) 6/53 (11%) 0/66 (0%) |
|POLY-3 RATE (b) | 26/46.93 17/39.21 13/40.87 6/37.78 6/25.83 0/9.33 |
|POLY-3 PERCENT (g) | 55.4% 43.4% 31.8% 15.9% 23.2% 0.0% |
|TERMINAL (d) | 14/27 (52%) 5/17 (29%) 5/24 (21%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 313 328 455 604 474 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.201N P=0.480N P=0.048N* P=0.005N** P=0.288 P=0.399N |
|POLY 3 | P<0.001N** P=0.179N P=0.018N* P<0.001N** P=0.008N** P=0.038N* |
|POLY 1.5 | P<0.001N** P=0.144N P=0.012N* P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P=0.005N** P=0.216N P=0.027N* P<0.001N** P=0.127N P=0.344N |
|LOGISTIC REGRESSION| P<0.001N** P=0.100N P=0.011N* P<0.001N** P=0.004N** P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.076N P=0.008N** P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.033N* (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Inflammation Granulomatous |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 3/53 (6%) 2/51 (4%) 1/53 (2%) 0/53 (0%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 3/42.81 2/33.79 1/38.31 0/36.73 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 7.0% 5.9% 2.6% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 555 525 567 --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.146N P=0.650N P=0.363N P=0.182N P=0.422N P=0.958N |
|POLY 3 | P=0.078N P=0.606N P=0.346N P=0.148N P=0.256N P=0.486N |
|POLY 1.5 | P=0.066N P=0.579N P=0.330N P=0.137N P=0.185N P=0.306N |
|POLY 6 | P=0.078N P=0.633N P=0.362N P=0.168N P=0.377N P=0.606N |
|LOGISTIC REGRESSION| P=0.017N* P=0.473N P=0.286N P=0.117N P=0.149N P=0.377N |
|COCH-ARM / FISHERS | P=0.030N* P=0.518N P=0.309N P=0.121N P=0.121N P=0.086N |
|ORDER RESTRICTED | P=0.470N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 48
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mesentery: Artery |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/35 (3%) 1/45 (2%) 9/49 (18%) 9/52 (17%) 3/63 (5%) |
|POLY-3 RATE (b) | 0/41.89 1/24.05 1/31.46 9/36.50 9/28.19 3/11.22 |
|POLY-3 PERCENT (g) | 0.0% 4.2% 3.2% 24.7% 31.9% 26.7% |
|TERMINAL (d) | 0/27 (0%) 1/13 (8%) 1/20 (5%) 4/15 (27%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) 726 (T) 537 450 267 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.354 P=0.440 P<0.001 ** P<0.001 ** P=0.005 ** |
|POLY 3 | P<0.001 ** P=0.391 P=0.443 P<0.001 ** P<0.001 ** P=0.028 * |
|POLY 1.5 | P<0.001 ** P=0.399 P=0.452 P<0.001 ** P<0.001 ** P=0.047 * |
|POLY 6 | P<0.001 ** P=0.383 P=0.435 P<0.001 ** P<0.001 ** P=0.020 * |
|LOGISTIC REGRESSION| P=0.002 ** P=0.354 P=0.440 P<0.001 ** P=0.003 ** P=0.113 |
|COCH-ARM / FISHERS | P=0.163 P=0.398 P=0.459 P<0.001 ** P<0.001 ** P=0.157 |
|ORDER RESTRICTED | P=0.042 * (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Mesentery: Fat |
| Necrosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 0/35 (0%) 0/45 (0%) 3/49 (6%) 0/52 (0%) 3/63 (5%) |
|POLY-3 RATE (b) | 1/41.89 0/24.05 0/31.46 3/35.26 0/23.55 3/11.49 |
|POLY-3 PERCENT (g) | 2.4% 0.0% 0.0% 8.5% 0.0% 26.1% |
|TERMINAL (d) | 1/27 (4%) 0/13 (0%) 0/20 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) --- --- 651 --- 233 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.646N P=0.560N P=0.189 P=1.000N P=0.009 ** |
|POLY 3 | P=0.105 P=0.609N P=0.557N P=0.245 P=0.607N P=0.072 |
|POLY 1.5 | P=0.122 P=0.601N P=0.548N P=0.256 P=0.562N P=0.132 |
|POLY 6 | P=0.061 P=0.616N P=0.564N P=0.226 P=0.664N P=0.048 * |
|LOGISTIC REGRESSION| P=0.092 (e) (e) P=0.227 (e) P=0.313 |
|COCH-ARM / FISHERS | P=0.197 P=0.602N P=0.541N P=0.280 P=0.505N P=0.377 |
|ORDER RESTRICTED | P=0.005 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 49
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Nose |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 17/53 (32%) 15/51 (29%) 16/53 (30%) 10/53 (19%) 22/53 (42%) 11/66 (17%) |
|POLY-3 RATE (b) | 17/45.19 15/37.47 16/42.04 10/39.05 22/34.45 11/17.92 |
|POLY-3 PERCENT (g) | 37.6% 40.0% 38.1% 25.6% 63.9% 61.4% |
|TERMINAL (d) | 10/27 (37%) 3/17 (18%) 6/24 (25%) 5/15 (33%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 364 408 541 337 226 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.298 P=0.501 P=0.431N P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.004 ** P=0.501 P=0.572 P=0.168N P=0.013 * P=0.113 |
|POLY 1.5 | P=0.062 P=0.553 P=0.573N P=0.138N P=0.050 P=0.476 |
|POLY 6 | P<0.001 ** P=0.470 P=0.554 P=0.224N P=0.002 ** P=0.028 * |
|LOGISTIC REGRESSION| P=0.157 P=0.548N P=0.527N P=0.118N P=0.077 P=0.487 |
|COCH-ARM / FISHERS | P=0.133N P=0.468N P=0.500N P=0.090N P=0.210 P=0.040N* |
|ORDER RESTRICTED | P=0.078 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Nose: Glands |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 2/53 (4%) 0/66 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 2/24.74 0/9.33 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 8.1% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- 582 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.003 ** (e) (e) (e) P=0.066 (e) |
|POLY 3 | P=0.016 * (e) (e) (e) P=0.144 (e) |
|POLY 1.5 | P=0.056 (e) (e) (e) P=0.180 (e) |
|POLY 6 | P=0.007 ** (e) (e) (e) P=0.107 (e) |
|LOGISTIC REGRESSION| P=0.092 (e) (e) (e) P=0.177 (e) |
|COCH-ARM / FISHERS | P=0.281 (e) (e) (e) P=0.248 (e) |
|ORDER RESTRICTED | P=0.313 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 50
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Nose: Olfactory Epithelium |
| Metaplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 2/51 (4%) 1/53 (2%) 3/53 (6%) 8/53 (15%) 1/66 (2%) |
|POLY-3 RATE (b) | 0/41.89 2/33.18 1/37.79 3/37.26 8/27.67 1/10.02 |
|POLY-3 PERCENT (g) | 0.0% 6.0% 2.7% 8.1% 28.9% 10.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 1/24 (4%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 639 726 (T) 567 397 491 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.169 P=0.477 P=0.058 P<0.001 ** P=0.150 |
|POLY 3 | P<0.001 ** P=0.189 P=0.479 P=0.098 P<0.001 ** P=0.306 |
|POLY 1.5 | P=0.002 ** P=0.200 P=0.487 P=0.105 P<0.001 ** P=0.377 |
|POLY 6 | P<0.001 ** P=0.179 P=0.472 P=0.088 P<0.001 ** P=0.268 |
|LOGISTIC REGRESSION| P=0.007 ** P=0.207 P=0.477 P=0.101 P=0.003 ** P=0.549 |
|COCH-ARM / FISHERS | P=0.212 P=0.238 P=0.500 P=0.121 P=0.003 ** P=0.555 |
|ORDER RESTRICTED | P=0.091 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Nose: Respiratory Epithelium |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 8/53 (15%) 11/51 (22%) 5/53 (9%) 8/53 (15%) 16/53 (30%) 9/66 (14%) |
|POLY-3 RATE (b) | 8/43.10 11/36.20 5/38.28 8/38.81 16/31.73 9/16.16 |
|POLY-3 PERCENT (g) | 18.6% 30.4% 13.1% 20.6% 50.4% 55.7% |
|TERMINAL (d) | 5/27 (19%) 2/17 (12%) 3/24 (13%) 4/15 (27%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 564 374 608 541 397 289 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.095 P=0.368N P=0.284 P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.165 P=0.355N P=0.518 P=0.003 ** P=0.020 * |
|POLY 1.5 | P=0.003 ** P=0.191 P=0.324N P=0.548 P=0.010 * P=0.110 |
|POLY 6 | P<0.001 ** P=0.152 P=0.387N P=0.468 P<0.001 ** P=0.005 ** |
|LOGISTIC REGRESSION| P=0.005 ** P=0.206 P=0.347N P=0.544 P=0.013 * P=0.050 |
|COCH-ARM / FISHERS | P=0.351 P=0.274 P=0.278N P=0.607N P=0.052 P=0.512N |
|ORDER RESTRICTED | P=0.015 * (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 51
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Nose: Squamous Epithelium |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 1/53 (2%) 0/53 (0%) 2/53 (4%) 1/66 (2%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 1/38.31 0/36.73 2/24.99 1/9.90 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 2.6% 0.0% 8.0% 10.1% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 567 --- 565 545 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.476 (e) P=0.113 P=0.032 * |
|POLY 3 | P=0.034 * (e) P=0.482 (e) P=0.145 P=0.305 |
|POLY 1.5 | P=0.056 (e) P=0.488 (e) P=0.181 P=0.376 |
|POLY 6 | P=0.029 * (e) P=0.477 (e) P=0.108 P=0.267 |
|LOGISTIC REGRESSION| P=0.104 (e) P=0.531 (e) P=0.261 P=0.382 |
|COCH-ARM / FISHERS | P=0.184 (e) P=0.500 (e) P=0.248 P=0.555 |
|ORDER RESTRICTED | P=0.196 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Oral Mucosa: Gingival |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 11/53 (21%) 10/51 (20%) 20/53 (38%) 24/53 (45%) 27/53 (51%) 18/66 (27%) |
|POLY-3 RATE (b) | 11/43.10 10/37.28 20/44.05 24/42.02 27/37.13 18/22.91 |
|POLY-3 PERCENT (g) | 25.5% 26.8% 45.4% 57.1% 72.7% 78.6% |
|TERMINAL (d) | 7/27 (26%) 2/17 (12%) 9/24 (38%) 10/15 (67%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 582 70 408 480 397 222 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.345 P=0.026 * P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.549 P=0.038 * P=0.002 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.578 P=0.038 * P=0.002 ** P<0.001 ** P=0.003 ** |
|POLY 6 | P<0.001 ** P=0.528 P=0.039 * P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.539N P=0.038 * P=0.002 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P=0.219 P=0.540N P=0.043 * P=0.006 ** P<0.001 ** P=0.273 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 52
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Ovary |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 46/53 (87%) 34/51 (67%) 43/53 (81%) 42/53 (79%) 7/53 (13%) 9/65 (14%) |
|POLY-3 RATE (b) | 46/50.65 34/42.80 43/49.57 42/48.77 7/27.77 9/17.30 |
|POLY-3 PERCENT (g) | 90.8% 79.4% 86.8% 86.1% 25.2% 52.0% |
|TERMINAL (d) | 25/27 (93%) 13/17 (77%) 21/24 (88%) 13/15 (87%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 275 399 367 337 217 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.075 P=0.393 P=0.414 P=0.071 P=0.408N P=0.014 * |
|POLY 3 | P<0.001N** P=0.081N P=0.361N P=0.326N P<0.001N** P<0.001N** |
|POLY 1.5 | P<0.001N** P=0.046N* P=0.350N P=0.335N P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.140N P=0.390N P=0.332N P<0.001N** P=0.257N |
|LOGISTIC REGRESSION| P<0.001N** P=0.052N P=0.375N P=0.345N P<0.001N** P<0.001N** |
|COCH-ARM / FISHERS | P<0.001N** P=0.013N* P=0.299N P=0.219N P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P<0.001N** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Ovary |
| Cyst |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 19/53 (36%) 12/51 (24%) 15/53 (28%) 19/53 (36%) 8/53 (15%) 13/65 (20%) |
|POLY-3 RATE (b) | 19/44.54 12/34.68 15/39.84 19/42.00 8/27.70 13/19.19 |
|POLY-3 PERCENT (g) | 42.7% 34.6% 37.7% 45.2% 28.9% 67.7% |
|TERMINAL (d) | 13/27 (48%) 4/17 (24%) 10/24 (42%) 5/15 (33%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 313 594 455 534 523 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.511N P=0.423N P=0.131 P=0.020 * P<0.001 ** |
|POLY 3 | P=0.269 P=0.307N P=0.401N P=0.490 P=0.178N P=0.082 |
|POLY 1.5 | P=0.438N P=0.243N P=0.351N P=0.501 P=0.064N P=0.429 |
|POLY 6 | P=0.055 P=0.353N P=0.445N P=0.485 P=0.458N P=0.017 * |
|LOGISTIC REGRESSION| P=0.148 P=0.287N P=0.371N P=0.486 P=0.154N P=0.199 |
|COCH-ARM / FISHERS | P=0.019N* P=0.123N P=0.266N P=0.580N P=0.012N* P=0.043N* |
|ORDER RESTRICTED | P=0.045 * (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 53
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Ovary |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 3/53 (6%) 3/53 (6%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 3/38.45 3/38.25 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 7.8% 7.8% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 2/24 (8%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 504 548 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.637 (e) P=0.103 P=0.105 (e) (e) |
|POLY 3 | P=0.596 (e) P=0.103 P=0.102 (e) (e) |
|POLY 1.5 | P=0.396N (e) P=0.109 P=0.108 (e) (e) |
|POLY 6 | P=0.278 (e) P=0.098 P=0.095 (e) (e) |
|LOGISTIC REGRESSION| P=0.196N (e) P=0.115 P=0.141 (e) (e) |
|COCH-ARM / FISHERS | P=0.128N (e) P=0.121 P=0.121 (e) (e) |
|ORDER RESTRICTED | P=0.555 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Ovary |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 3/53 (6%) 3/53 (6%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 0/41.89 1/32.58 3/38.30 3/38.09 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 0.0% 3.1% 7.8% 7.9% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 2/24 (8%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) 572 539 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.620 P=0.408 P=0.101 P=0.101 (e) (e) |
|POLY 3 | P=0.533N P=0.450 P=0.103 P=0.102 (e) (e) |
|POLY 1.5 | P=0.311N P=0.464 P=0.108 P=0.107 (e) (e) |
|POLY 6 | P=0.370 P=0.437 P=0.098 P=0.094 (e) (e) |
|LOGISTIC REGRESSION| P=0.242N P=0.408 P=0.106 P=0.135 (e) (e) |
|COCH-ARM / FISHERS | P=0.085N P=0.490 P=0.121 P=0.121 (e) (e) |
|ORDER RESTRICTED | P=0.578 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 54
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pancreas |
| Edema |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 1/53 (2%) 0/53 (0%) 4/53 (8%) 19/65 (29%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 1/38.13 0/36.73 4/25.96 19/26.29 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 2.6% 0.0% 15.4% 72.3% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 632 --- 383 233 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) P=0.466 (e) P=0.006 ** P<0.001 ** |
|POLY 3 | P<0.001 ** (e) P=0.481 (e) P=0.021 * P<0.001 ** |
|POLY 1.5 | P<0.001 ** (e) P=0.488 (e) P=0.034 * P<0.001 ** |
|POLY 6 | P<0.001 ** (e) P=0.475 (e) P=0.011 * P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** (e) P=0.504 (e) P=0.092 P=0.029 * |
|COCH-ARM / FISHERS | P<0.001 ** (e) P=0.500 (e) P=0.059 P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pancreas |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 2/65 (3%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 0/23.94 2/11.15 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 0.0% 17.9% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- --- 294 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.007 ** (e) (e) (e) (e) P=0.183 |
|POLY 3 | P=0.102 (e) (e) (e) (e) P=0.094 |
|POLY 1.5 | P=0.043 * (e) (e) (e) (e) P=0.135 |
|POLY 6 | P=0.194 (e) (e) (e) (e) P=0.076 |
|LOGISTIC REGRESSION| P=0.144 (e) (e) (e) (e) P=0.782 |
|COCH-ARM / FISHERS | P=0.019 * (e) (e) (e) (e) P=0.301 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 55
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pancreas |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 5/51 (10%) 4/53 (8%) 3/53 (6%) 2/53 (4%) 6/65 (9%) |
|POLY-3 RATE (b) | 1/42.38 5/33.91 4/38.31 3/37.11 2/24.78 6/14.33 |
|POLY-3 PERCENT (g) | 2.4% 14.8% 10.4% 8.1% 8.1% 41.9% |
|TERMINAL (d) | 0/27 (0%) 3/17 (18%) 3/24 (13%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 582 484 567 667 555 233 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.045 * P=0.144 P=0.193 P=0.203 P<0.001 ** |
|POLY 3 | P=0.065 P=0.057 P=0.148 P=0.259 P=0.326 P=0.003 ** |
|POLY 1.5 | P=0.109 P=0.067 P=0.159 P=0.275 P=0.400 P=0.010 * |
|POLY 6 | P=0.026 * P=0.049 * P=0.138 P=0.234 P=0.239 P<0.001 ** |
|LOGISTIC REGRESSION| P=0.146 P=0.085 P=0.162 P=0.275 P=0.499 P=0.278 |
|COCH-ARM / FISHERS | P=0.320 P=0.094 P=0.181 P=0.309 P=0.500 P=0.096 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pancreas: Acinus |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 1/53 (2%) 5/51 (10%) 3/53 (6%) 5/53 (9%) 9/53 (17%) 8/65 (12%) |
|POLY-3 RATE (b) | 1/41.89 5/33.91 3/37.79 5/37.54 9/29.33 8/16.01 |
|POLY-3 PERCENT (g) | 2.4% 14.8% 7.9% 13.3% 30.7% 50.0% |
|TERMINAL (d) | 1/27 (4%) 3/17 (18%) 3/24 (13%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 484 726 (T) 628 349 222 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.039 * P=0.262 P=0.038 * P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.059 P=0.268 P=0.077 P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.068 P=0.282 P=0.085 P=0.002 ** P=0.002 ** |
|POLY 6 | P<0.001 ** P=0.051 P=0.255 P=0.066 P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P=0.009 ** P=0.070 P=0.262 P=0.066 P=0.028 * P=0.099 |
|COCH-ARM / FISHERS | P=0.027 * P=0.094 P=0.309 P=0.103 P=0.008 ** P=0.033 * |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 56
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pancreas: Acinus |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 2/42.36 0/32.58 0/37.79 0/36.73 0/23.94 0/9.28 |
|POLY-3 PERCENT (g) | 4.7% 0.0% 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 639 --- --- --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.521N P=0.327N P=0.282N P=0.310N P=0.647N P=1.000N |
|POLY 3 | P=0.233N P=0.299N P=0.263N P=0.270N P=0.379N P=0.565N |
|POLY 1.5 | P=0.238N P=0.281N P=0.253N P=0.258N P=0.311N P=0.424N |
|POLY 6 | P=0.187N P=0.320N P=0.274N P=0.291N P=0.483N P=0.651N |
|LOGISTIC REGRESSION| P=0.307N P=0.274N P=0.247N P=0.252N P=0.378N P=0.773N |
|COCH-ARM / FISHERS | P=0.188N P=0.257N P=0.248N P=0.248N P=0.248N P=0.200N |
|ORDER RESTRICTED | P=0.414N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pancreas: Acinus |
| Vacuolization Cytoplasmic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 8/53 (15%) 39/53 (74%) 49/53 (92%) 43/65 (66%) |
|POLY-3 RATE (b) | 0/41.89 1/32.58 8/38.89 39/44.58 49/49.61 43/44.52 |
|POLY-3 PERCENT (g) | 0.0% 3.1% 20.6% 87.5% 98.8% 96.6% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 4/24 (17%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) 572 534 267 203 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.408 P=0.003 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.450 P=0.002 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.464 P=0.003 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.437 P=0.002 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.408 P=0.003 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.490 P=0.003 ** P<0.001 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 57
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pancreas: Artery |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 2/51 (4%) 2/53 (4%) 21/53 (40%) 14/53 (26%) 4/65 (6%) |
|POLY-3 RATE (b) | 0/41.89 2/32.58 2/37.79 21/39.86 14/31.26 4/12.01 |
|POLY-3 PERCENT (g) | 0.0% 6.1% 5.3% 52.7% 44.8% 33.3% |
|TERMINAL (d) | 0/27 (0%) 2/17 (12%) 2/24 (8%) 7/15 (47%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) 726 (T) 567 447 329 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.143 P=0.212 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.185 P=0.214 P<0.001 ** P<0.001 ** P=0.009 ** |
|POLY 1.5 | P<0.001 ** P=0.199 P=0.223 P<0.001 ** P<0.001 ** P=0.018 * |
|POLY 6 | P<0.001 ** P=0.173 P=0.206 P<0.001 ** P<0.001 ** P=0.006 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.143 P=0.212 P<0.001 ** P<0.001 ** P=0.016 * |
|COCH-ARM / FISHERS | P=0.206 P=0.238 P=0.248 P<0.001 ** P<0.001 ** P=0.088 |
|ORDER RESTRICTED | P=0.007 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pancreas: Duct |
| Dilatation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 1/53 (2%) 3/53 (6%) 0/65 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 1/36.73 3/25.31 0/9.28 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 2.7% 11.9% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 726 (T) 447 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) P=0.383 P=0.021 * (e) |
|POLY 3 | P=0.004 ** (e) (e) P=0.474 P=0.055 (e) |
|POLY 1.5 | P=0.028 * (e) (e) P=0.483 P=0.077 (e) |
|POLY 6 | P<0.001 ** (e) (e) P=0.459 P=0.034 * (e) |
|LOGISTIC REGRESSION| P=0.060 (e) (e) P=0.383 P=0.117 (e) |
|COCH-ARM / FISHERS | P=0.283 (e) (e) P=0.500 P=0.121 (e) |
|ORDER RESTRICTED | P=0.290 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 58
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pituitary Gland |
| Angiectasis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 23/53 (43%) 13/51 (25%) 19/52 (37%) 7/53 (13%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 23/44.91 13/34.62 19/40.23 7/38.05 0/23.94 0/9.27 |
|POLY-3 PERCENT (g) | 51.2% 37.6% 47.2% 18.4% 0.0% 0.0% |
|TERMINAL (d) | 15/27 (56%) 6/17 (35%) 13/24 (54%) 3/15 (20%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 564 611 548 537 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.012N* P=0.364N P=0.491N P=0.030N* P=0.099N P=0.778N |
|POLY 3 | P<0.001N** P=0.156N P=0.439N P<0.001N** P<0.001N** P=0.050N |
|POLY 1.5 | P<0.001N** P=0.105N P=0.382N P<0.001N** P<0.001N** P<0.001N** |
|POLY 6 | P<0.001N** P=0.219N P=0.507N P=0.003N** P=0.002N** P=0.356N |
|LOGISTIC REGRESSION| P<0.001N** P=0.171N P=0.443N P=0.002N** P<0.001N** P=0.067N |
|COCH-ARM / FISHERS | P<0.001N** P=0.043N* P=0.302N P<0.001N** P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.041N* (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pituitary Gland |
| Vacuolization Cytoplasmic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 1/51 (2%) 0/52 (0%) 5/53 (9%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 2/41.89 1/32.58 0/37.62 5/37.69 0/23.94 0/9.27 |
|POLY-3 PERCENT (g) | 4.8% 3.1% 0.0% 13.3% 0.0% 0.0% |
|TERMINAL (d) | 2/27 (7%) 1/17 (6%) 0/24 (0%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 726 (T) --- 594 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.291 P=0.661N P=0.264N P=0.084 P=1.000N P=1.000N |
|POLY 3 | P=0.590N P=0.586N P=0.261N P=0.173 P=0.377N P=0.563N |
|POLY 1.5 | P=0.330N P=0.563N P=0.254N P=0.187 P=0.310N P=0.423N |
|POLY 6 | P=0.261 P=0.610N P=0.269N P=0.153 P=0.478N P=0.650N |
|LOGISTIC REGRESSION| P=0.649N P=0.661N (e) P=0.155 (e) (e) |
|COCH-ARM / FISHERS | P=0.080N P=0.515N P=0.252N P=0.219 P=0.248N P=0.200N |
|ORDER RESTRICTED | P=0.599N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 59
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 11/53 (21%) 14/51 (27%) 19/52 (37%) 18/53 (34%) 4/53 (8%) 1/65 (2%) |
|POLY-3 RATE (b) | 11/43.08 14/34.98 19/41.75 18/39.76 4/25.18 1/10.02 |
|POLY-3 PERCENT (g) | 25.5% 40.0% 45.5% 45.3% 15.9% 10.0% |
|TERMINAL (d) | 6/27 (22%) 7/17 (41%) 8/24 (33%) 7/15 (47%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 564 525 471 390 520 456 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.033 * P=0.059 P=0.041 * P=0.007 ** P=0.043 * P=0.289 |
|POLY 3 | P=0.087N P=0.127 P=0.040 * P=0.043 * P=0.275N P=0.338N |
|POLY 1.5 | P=0.002N** P=0.167 P=0.043 * P=0.057 P=0.136N P=0.074N |
|POLY 6 | P=0.476 P=0.098 P=0.040 * P=0.027 * P=0.545N P=0.597 |
|LOGISTIC REGRESSION| P=0.041N* P=0.105 P=0.036 * P=0.037 * P=0.572N P=0.625N |
|COCH-ARM / FISHERS | P<0.001N** P=0.285 P=0.057 P=0.095 P=0.046N* P<0.001N** |
|ORDER RESTRICTED | P=0.238N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Skin |
| Cyst Epithelial Inclusion |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 0/53 (0%) 2/53 (4%) 1/53 (2%) 0/66 (0%) |
|POLY-3 RATE (b) | 0/41.89 1/32.58 0/37.79 2/36.73 1/24.34 0/9.33 |
|POLY-3 PERCENT (g) | 0.0% 3.1% 0.0% 5.4% 4.1% 0.0% |
|TERMINAL (d) | 0/27 (0%) 1/17 (6%) 0/24 (0%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 726 (T) --- 726 (T) 611 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.015 * P=0.408 (e) P=0.120 P=0.313 (e) |
|POLY 3 | P=0.238 P=0.450 (e) P=0.209 P=0.398 (e) |
|POLY 1.5 | P=0.443 P=0.464 (e) P=0.219 P=0.442 (e) |
|POLY 6 | P=0.089 P=0.437 (e) P=0.193 P=0.342 (e) |
|LOGISTIC REGRESSION| P=0.151 P=0.408 (e) P=0.120 P=0.471 (e) |
|COCH-ARM / FISHERS | P=0.423N P=0.490 (e) P=0.248 P=0.500 (e) |
|ORDER RESTRICTED | P=0.572 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 60
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Spleen |
| Hematopoietic Cell Proliferation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 49/53 (92%) 44/51 (86%) 49/53 (92%) 52/53 (98%) 50/53 (94%) 43/65 (66%) |
|POLY-3 RATE (b) | 49/51.71 44/45.96 49/50.62 52/52.55 50/50.38 43/45.37 |
|POLY-3 PERCENT (g) | 94.8% 95.7% 96.8% 99.0% 99.3% 94.8% |
|TERMINAL (d) | 26/27 (96%) 17/17 (100%) 23/24 (96%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 70 408 41 267 91 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.060 P=0.235 P=0.006 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.479 P=0.621 P=0.491 P=0.217 P=0.185 P=0.730 |
|POLY 1.5 | P=0.101N P=0.592N P=0.485 P=0.196 P=0.239 P=0.144N |
|POLY 6 | P=0.150 P=0.510 P=0.553 P=0.267 P=0.215 P=0.396 |
|LOGISTIC REGRESSION| P=0.226N P=0.474N P=0.527 P=0.167 P=0.195 P=0.337N |
|COCH-ARM / FISHERS | P<0.001N** P=0.241N P=0.642N P=0.181 P=0.500 P<0.001N** |
|ORDER RESTRICTED | P=0.229 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Spleen |
| Pigmentation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 52/53 (98%) 50/51 (98%) 52/53 (98%) 50/53 (94%) 50/53 (94%) 59/65 (91%) |
|POLY-3 RATE (b) | 52/53.00 50/50.86 52/52.23 50/51.80 50/51.92 59/59.63 |
|POLY-3 PERCENT (g) | 98.1% 98.3% 99.6% 96.5% 96.3% 99.0% |
|TERMINAL (d) | 26/27 (96%) 17/17 (100%) 24/24 (100%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 70 63 41 166 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.025 * P=0.231 P=0.032 * P<0.001 ** P<0.001 ** |
|POLY 3 | P=0.564N P=0.752 P=0.591 P=0.547N P=0.513N P=0.693 |
|POLY 1.5 | P=0.265N P=0.761 P=0.668 P=0.422N P=0.406N P=0.619N |
|POLY 6 | P=0.455 P=0.734 P=0.524 P=0.748N P=0.698N P=0.517 |
|LOGISTIC REGRESSION| P=0.047N* P=0.684N P=0.740 P=0.301N P=0.109N P=0.397N |
|COCH-ARM / FISHERS | P=0.014N* P=0.743N P=0.752N P=0.309N P=0.309N P=0.096N |
|ORDER RESTRICTED | P=0.490N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 61
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Spleen: Lymphoid Follicle |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 5/51 (10%) 2/53 (4%) 5/53 (9%) 3/53 (6%) 9/65 (14%) |
|POLY-3 RATE (b) | 4/43.27 5/35.74 2/39.13 5/38.68 3/26.31 9/17.28 |
|POLY-3 PERCENT (g) | 9.3% 14.0% 5.1% 12.9% 11.4% 52.1% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 564 275 399 390 313 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.332 P=0.406N P=0.378 P=0.461 P<0.001 ** |
|POLY 3 | P=0.009 ** P=0.381 P=0.384N P=0.429 P=0.545 P=0.002 ** |
|POLY 1.5 | P=0.022 * P=0.411 P=0.365N P=0.455 P=0.643N P=0.015 * |
|POLY 6 | P=0.002 ** P=0.348 P=0.406N P=0.387 P=0.376 P<0.001 ** |
|LOGISTIC REGRESSION| P=0.399N P=0.642 P=0.279N P=0.539 P=0.288N P=0.682 |
|COCH-ARM / FISHERS | P=0.119 P=0.475 P=0.339N P=0.500 P=0.500N P=0.216 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Spleen: Red Pulp |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 1/53 (2%) 2/65 (3%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 1/24.80 2/11.23 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 4.0% 17.8% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- 373 209 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.009 ** (e) (e) (e) P=0.492 P=0.269 |
|POLY 3 | P=0.021 * (e) (e) (e) P=0.401 P=0.094 |
|POLY 1.5 | P=0.014 * (e) (e) (e) P=0.445 P=0.136 |
|POLY 6 | P=0.037 * (e) (e) (e) P=0.345 P=0.076 |
|LOGISTIC REGRESSION| P=0.195 (e) (e) (e) P=0.712 P=0.945 |
|COCH-ARM / FISHERS | P=0.019 * (e) (e) (e) P=0.500 P=0.301 |
|ORDER RESTRICTED | P=0.004 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 62
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Edema |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 2/53 (4%) 1/53 (2%) 0/65 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 2/37.16 1/24.14 0/9.25 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.4% 4.1% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 653 672 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.013 * (e) (e) P=0.182 P=0.196 (e) |
|POLY 3 | P=0.120 (e) (e) P=0.211 P=0.397 (e) |
|POLY 1.5 | P=0.292 (e) (e) P=0.220 P=0.442 (e) |
|POLY 6 | P=0.031 * (e) (e) P=0.198 P=0.340 (e) |
|LOGISTIC REGRESSION| P=0.188 (e) (e) P=0.215 P=0.303 (e) |
|COCH-ARM / FISHERS | P=0.607N (e) (e) P=0.248 P=0.500 (e) |
|ORDER RESTRICTED | P=0.530 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 1/51 (2%) 3/53 (6%) 11/53 (21%) 4/53 (8%) 9/65 (14%) |
|POLY-3 RATE (b) | 4/41.89 1/32.86 3/38.97 11/39.95 4/26.09 9/16.84 |
|POLY-3 PERCENT (g) | 9.6% 3.0% 7.7% 27.5% 15.3% 53.4% |
|TERMINAL (d) | 4/27 (15%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 651 548 552 349 217 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.332N P=0.562N P=0.014 * P=0.006 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.260N P=0.540N P=0.031 * P=0.375 P=0.002 ** |
|POLY 1.5 | P=0.005 ** P=0.237N P=0.527N P=0.034 * P=0.497 P=0.015 * |
|POLY 6 | P<0.001 ** P=0.282N P=0.548N P=0.029 * P=0.225 P<0.001 ** |
|LOGISTIC REGRESSION| P=0.047 * P=0.299N P=0.541N P=0.031 * P=0.515 P=0.198 |
|COCH-ARM / FISHERS | P=0.095 P=0.194N P=0.500N P=0.046 * P=0.642N P=0.216 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 63
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 0/51 (0%) 2/53 (4%) 4/53 (8%) 0/53 (0%) 1/65 (2%) |
|POLY-3 RATE (b) | 2/41.89 0/32.58 2/38.88 4/37.44 0/23.94 1/9.95 |
|POLY-3 PERCENT (g) | 4.8% 0.0% 5.1% 10.7% 0.0% 10.1% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) --- 548 651 --- 482 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.056 P=0.344N P=0.650 P=0.177 P=1.000N P=0.186 |
|POLY 3 | P=0.548 P=0.296N P=0.668 P=0.285 P=0.377N P=0.529 |
|POLY 1.5 | P=0.471N P=0.280N P=0.676 P=0.302 P=0.310N P=0.699 |
|POLY 6 | P=0.313 P=0.314N P=0.661 P=0.260 P=0.478N P=0.415 |
|LOGISTIC REGRESSION| P=0.597 (e) P=0.696 P=0.248 (e) P=0.554 |
|COCH-ARM / FISHERS | P=0.204N P=0.257N P=0.691N P=0.339 P=0.248N P=0.423N |
|ORDER RESTRICTED | P=0.500 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Mineralization |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 1/53 (2%) 0/53 (0%) 2/65 (3%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 1/37.60 0/23.94 2/11.13 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 2.7% 0.0% 18.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 367 --- 267 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.027 * (e) (e) P=0.500 (e) P=0.205 |
|POLY 3 | P=0.102 (e) (e) P=0.478 (e) P=0.094 |
|POLY 1.5 | P=0.075 (e) (e) P=0.486 (e) P=0.135 |
|POLY 6 | P=0.114 (e) (e) P=0.465 (e) P=0.076 |
|LOGISTIC REGRESSION| P=0.358 (e) (e) P=0.661 (e) P=0.817 |
|COCH-ARM / FISHERS | P=0.070 (e) (e) P=0.500 (e) P=0.301 |
|ORDER RESTRICTED | P=0.004 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 64
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Ulcer |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 0/51 (0%) 1/53 (2%) 1/53 (2%) 0/53 (0%) 1/65 (2%) |
|POLY-3 RATE (b) | 2/41.89 0/32.58 1/38.31 1/37.01 0/23.94 1/9.95 |
|POLY-3 PERCENT (g) | 4.8% 0.0% 2.6% 2.7% 0.0% 10.1% |
|TERMINAL (d) | 2/27 (7%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) --- 567 653 --- 482 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.099 P=0.344N P=0.541N P=0.648N P=1.000N P=0.186 |
|POLY 3 | P=0.524N P=0.296N P=0.531N P=0.543N P=0.377N P=0.529 |
|POLY 1.5 | P=0.511N P=0.280N P=0.520N P=0.528N P=0.310N P=0.699 |
|POLY 6 | P=0.522N P=0.314N P=0.541N P=0.567N P=0.478N P=0.415 |
|LOGISTIC REGRESSION| P=0.549 (e) P=0.525N P=0.583N (e) P=0.554 |
|COCH-ARM / FISHERS | P=0.389N P=0.257N P=0.500N P=0.500N P=0.248N P=0.423N |
|ORDER RESTRICTED | P=0.367 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Stomach, Forestomach: Artery |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 2/53 (4%) 0/53 (0%) 0/65 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 2/37.24 0/23.94 0/9.25 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.4% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 602 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.519 (e) (e) P=0.181 (e) (e) |
|POLY 3 | P=0.446 (e) (e) P=0.211 (e) (e) |
|POLY 1.5 | P=0.641 (e) (e) P=0.220 (e) (e) |
|POLY 6 | P=0.180 (e) (e) P=0.198 (e) (e) |
|LOGISTIC REGRESSION| P=0.715 (e) (e) P=0.225 (e) (e) |
|COCH-ARM / FISHERS | P=0.441N (e) (e) P=0.248 (e) (e) |
|ORDER RESTRICTED | P=0.590 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 65
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Stomach, Glandular |
| Erosion |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 0/53 (0%) 0/53 (0%) 1/53 (2%) 2/65 (3%) |
|POLY-3 RATE (b) | 0/41.89 1/33.46 0/37.79 0/36.73 1/24.70 2/10.92 |
|POLY-3 PERCENT (g) | 0.0% 3.0% 0.0% 0.0% 4.1% 18.3% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 364 --- --- 447 237 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.012 * P=0.483 (e) (e) P=0.475 P=0.094 |
|POLY 3 | P=0.074 P=0.455 (e) (e) P=0.401 P=0.093 |
|POLY 1.5 | P=0.058 P=0.467 (e) (e) P=0.444 P=0.134 |
|POLY 6 | P=0.103 P=0.444 (e) (e) P=0.344 P=0.076 |
|LOGISTIC REGRESSION| P=0.354 P=0.690 (e) (e) P=0.663 P=0.580 |
|COCH-ARM / FISHERS | P=0.083 P=0.490 (e) (e) P=0.500 P=0.301 |
|ORDER RESTRICTED | P=0.011 * (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Stomach, Glandular |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/53 (0%) 1/53 (2%) 3/65 (5%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.73 1/24.70 3/12.13 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 4.1% 24.7% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- 447 233 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) (e) P=0.475 P=0.129 |
|POLY 3 | P=0.007 ** (e) (e) (e) P=0.401 P=0.030 * |
|POLY 1.5 | P=0.003 ** (e) (e) (e) P=0.444 P=0.051 |
|POLY 6 | P=0.014 * (e) (e) (e) P=0.344 P=0.022 * |
|LOGISTIC REGRESSION| P=0.101 (e) (e) (e) P=0.663 P=0.814 |
|COCH-ARM / FISHERS | P=0.004 ** (e) (e) (e) P=0.500 P=0.164 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 66
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Stomach, Glandular |
| Mineralization |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 12/53 (23%) 6/51 (12%) 6/53 (11%) 1/53 (2%) 6/53 (11%) 5/65 (8%) |
|POLY-3 RATE (b) | 12/45.97 6/34.71 6/41.20 1/36.81 6/26.38 5/13.58 |
|POLY-3 PERCENT (g) | 26.1% 17.3% 14.6% 2.7% 22.7% 36.8% |
|TERMINAL (d) | 3/27 (11%) 2/17 (12%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 313 443 443 707 447 267 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.004 ** P=0.313N P=0.180N P=0.010N* P=0.250 P=0.053 |
|POLY 3 | P=0.463 P=0.252N P=0.142N P=0.004N** P=0.486N P=0.378 |
|POLY 1.5 | P=0.471N P=0.199N P=0.124N P=0.002N** P=0.279N P=0.434N |
|POLY 6 | P=0.343 P=0.315N P=0.164N P=0.007N** P=0.441 P=0.170 |
|LOGISTIC REGRESSION| P=0.094N P=0.090N P=0.055N P<0.001N** P=0.113N P=0.033N* |
|COCH-ARM / FISHERS | P=0.102N P=0.113N P=0.098N P<0.001N** P=0.098N P=0.021N* |
|ORDER RESTRICTED | P=0.174 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thymus |
| Atrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 40/53 (75%) 44/51 (86%) 44/51 (86%) 49/51 (96%) 50/51 (98%) 57/59 (97%) |
|POLY-3 RATE (b) | 40/48.92 44/46.56 44/48.76 49/49.00 50/50.68 57/57.15 |
|POLY-3 PERCENT (g) | 81.8% 94.5% 90.3% 100.0% 98.7% 99.7% |
|TERMINAL (d) | 23/27 (85%) 17/17 (100%) 18/22 (82%) 15/15 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 275 399 261 166 91 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.003 ** P=0.079 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P=0.036 * P=0.162 P<0.001 ** P=0.002 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.037 * P=0.121 P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P=0.047 * P=0.248 P=0.002 ** P=0.004 ** P<0.001 ** |
|LOGISTIC REGRESSION| P<0.001 ** P=0.029 * P=0.086 P<0.001 ** P<0.001 ** P=0.002 ** |
|COCH-ARM / FISHERS | P<0.001 ** P=0.125 P=0.125 P=0.003 ** P<0.001 ** P<0.001 ** |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 67
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thymus |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 2/51 (4%) 0/51 (0%) 0/51 (0%) 0/59 (0%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 2/37.17 0/35.75 0/22.78 0/8.50 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 5.4% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/22 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- 399 --- --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.430N (e) P=0.234 (e) (e) (e) |
|POLY 3 | P=0.472N (e) P=0.211 (e) (e) (e) |
|POLY 1.5 | P=0.405N (e) P=0.217 (e) (e) (e) |
|POLY 6 | P=0.532N (e) P=0.204 (e) (e) (e) |
|LOGISTIC REGRESSION| P=0.145N (e) P=0.300 (e) (e) (e) |
|COCH-ARM / FISHERS | P=0.264N (e) P=0.238 (e) (e) (e) |
|ORDER RESTRICTED | P=0.689 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 7/53 (13%) 11/51 (22%) 13/53 (25%) 10/52 (19%) 15/52 (29%) 3/66 (5%) |
|POLY-3 RATE (b) | 7/43.53 11/34.81 13/40.75 10/39.26 15/31.04 3/11.81 |
|POLY-3 PERCENT (g) | 16.1% 31.6% 31.9% 25.5% 48.3% 25.4% |
|TERMINAL (d) | 3/27 (11%) 6/17 (35%) 6/24 (25%) 3/15 (20%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 555 534 455 548 373 321 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.051 P=0.073 P=0.120 P<0.001 ** P=0.034 * |
|POLY 3 | P=0.016 * P=0.086 P=0.070 P=0.215 P=0.002 ** P=0.415 |
|POLY 1.5 | P=0.213 P=0.113 P=0.082 P=0.235 P=0.009 ** P=0.528N |
|POLY 6 | P<0.001 ** P=0.066 P=0.060 P=0.183 P<0.001 ** P=0.237 |
|LOGISTIC REGRESSION| P=0.420 P=0.110 P=0.092 P=0.261 P=0.027 * P=0.512N |
|COCH-ARM / FISHERS | P=0.032N* P=0.193 P=0.107 P=0.284 P=0.041 * P=0.087N |
|ORDER RESTRICTED | P=0.211 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 68
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 0/52 (0%) 2/52 (4%) 1/66 (2%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 0/36.44 2/24.73 1/9.99 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 0.0% 8.1% 10.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 0/15 (0%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- --- 582 504 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** (e) (e) (e) P=0.066 P=0.128 |
|POLY 3 | P=0.009 ** (e) (e) (e) P=0.143 P=0.306 |
|POLY 1.5 | P=0.016 * (e) (e) (e) P=0.179 P=0.377 |
|POLY 6 | P=0.009 ** (e) (e) (e) P=0.106 P=0.268 |
|LOGISTIC REGRESSION| P=0.016 * (e) (e) (e) P=0.180 P=0.511 |
|COCH-ARM / FISHERS | P=0.072 (e) (e) (e) P=0.243 P=0.555 |
|ORDER RESTRICTED | P=0.135 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Hypertrophy |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 22/53 (42%) 35/51 (69%) 34/53 (64%) 38/52 (73%) 44/52 (85%) 37/66 (56%) |
|POLY-3 RATE (b) | 22/47.33 35/45.44 34/48.44 38/49.28 44/47.20 37/40.35 |
|POLY-3 PERCENT (g) | 46.5% 77.0% 70.2% 77.1% 93.2% 91.7% |
|TERMINAL (d) | 9/27 (33%) 11/17 (65%) 14/24 (58%) 11/15 (73%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 70 399 41 267 51 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P<0.001 ** P=0.017 * P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 3 | P<0.001 ** P<0.001 ** P=0.012 * P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 1.5 | P<0.001 ** P=0.002 ** P=0.011 * P<0.001 ** P<0.001 ** P<0.001 ** |
|POLY 6 | P<0.001 ** P<0.001 ** P=0.014 * P<0.001 ** P<0.001 ** P<0.001 ** |
|LOGISTIC REGRESSION| P=0.302 P=0.009 ** P=0.022 * P=0.002 ** P<0.001 ** P=0.137 |
|COCH-ARM / FISHERS | P=0.301 P=0.005 ** P=0.016 * P<0.001 ** P<0.001 ** P=0.082 |
|ORDER RESTRICTED | P<0.001 ** (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 69
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Tooth: Peridontal Tissue |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 29/29 (100%) 26/26 (100%) 33/33 (100%) 34/34 (100%) 29/29 (100%) 25/25 (100%) |
|POLY-3 RATE (b) | 29/29.00 26/26.00 33/33.00 34/34.00 29/29.00 25/25.00 |
|POLY-3 PERCENT (g) | 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% |
|TERMINAL (d) | 16/16 (100%) 8/8 (100%) 20/20 (100%) 10/10 (100%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 534 70 408 480 313 245 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | (e) (e) (e) (e) (e) (e) |
|POLY 3 | (e) (e) (e) (e) (e) (e) |
|POLY 1.5 | (e) (e) (e) (e) (e) (e) |
|POLY 6 | (e) (e) (e) (e) (e) (e) |
|LOGISTIC REGRESSION| (e) (e) (e) (e) (e) (e) |
|COCH-ARM / FISHERS | (e) (e) (e) (e) (e) (e) |
|ORDER RESTRICTED | (e) (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Urinary Bladder |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 8/53 (15%) 3/51 (6%) 2/53 (4%) 4/53 (8%) 1/52 (2%) 0/66 (0%) |
|POLY-3 RATE (b) | 8/43.36 3/33.27 2/37.79 4/37.84 1/24.28 0/9.33 |
|POLY-3 PERCENT (g) | 18.5% 9.0% 5.3% 10.6% 4.1% 0.0% |
|TERMINAL (d) | 3/27 (11%) 0/17 (0%) 2/24 (8%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 362 616 726 (T) 567 548 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.535N P=0.279N P=0.078N P=0.405N P=0.629N P=0.642N |
|POLY 3 | P=0.100N P=0.203N P=0.070N P=0.246N P=0.112N P=0.283N |
|POLY 1.5 | P=0.037N* P=0.170N P=0.060N P=0.222N P=0.052N P=0.073N |
|POLY 6 | P=0.203N P=0.237N P=0.083N P=0.287N P=0.262N P=0.503N |
|LOGISTIC REGRESSION| P=0.049N* P=0.160N P=0.060N P=0.203N P=0.052N P=0.136N |
|COCH-ARM / FISHERS | P=0.003N** P=0.113N P=0.046N* P=0.179N P=0.017N* P<0.001N** |
|ORDER RESTRICTED | P=0.267N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 70
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Urinary Bladder: Transitional Epithelium |
| Hyperplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 2/51 (4%) 0/53 (0%) 4/53 (8%) 1/52 (2%) 0/66 (0%) |
|POLY-3 RATE (b) | 4/42.40 2/33.22 0/37.79 4/37.31 1/24.28 0/9.33 |
|POLY-3 PERCENT (g) | 9.4% 6.0% 0.0% 10.7% 4.1% 0.0% |
|TERMINAL (d) | 1/27 (4%) 0/17 (0%) 0/24 (0%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 672 616 --- 636 548 --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.323 P=0.528N P=0.089N P=0.408 P=0.590 P=1.000 |
|POLY 3 | P=0.463N P=0.454N P=0.076N P=0.572 P=0.386N P=0.426N |
|POLY 1.5 | P=0.252N P=0.422N P=0.070N P=0.597 P=0.287N P=0.224N |
|POLY 6 | P=0.465 P=0.486N P=0.083N P=0.529 P=0.540N P=0.574N |
|LOGISTIC REGRESSION| P=0.378N P=0.442N P=0.078N P=0.549 P=0.425N P=0.765N |
|COCH-ARM / FISHERS | P=0.046N* P=0.358N P=0.059N P=0.642N P=0.187N P=0.037N* |
|ORDER RESTRICTED | P=0.466N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Uterus |
| Adenomyosis |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 1/51 (2%) 0/53 (0%) 3/53 (6%) 0/53 (0%) 1/66 (2%) |
|POLY-3 RATE (b) | 0/41.89 1/32.84 0/37.79 3/37.12 0/23.94 1/10.14 |
|POLY-3 PERCENT (g) | 0.0% 3.1% 0.0% 8.1% 0.0% 9.9% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- 659 --- 663 --- 415 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.015 * P=0.431 (e) P=0.059 (e) P=0.308 |
|POLY 3 | P=0.302 P=0.452 (e) P=0.098 (e) P=0.307 |
|POLY 1.5 | P=0.426 P=0.464 (e) P=0.105 (e) P=0.378 |
|POLY 6 | P=0.145 P=0.440 (e) P=0.088 (e) P=0.268 |
|LOGISTIC REGRESSION| P=0.299 P=0.466 (e) P=0.088 (e) P=0.744 |
|COCH-ARM / FISHERS | P=0.551N P=0.490 (e) P=0.121 (e) P=0.555 |
|ORDER RESTRICTED | P=0.243 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 71
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Uterus |
| Hemorrhage |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 0/53 (0%) 0/51 (0%) 0/53 (0%) 2/53 (4%) 0/53 (0%) 1/66 (2%) |
|POLY-3 RATE (b) | 0/41.89 0/32.58 0/37.79 2/37.11 0/23.94 1/10.02 |
|POLY-3 PERCENT (g) | 0.0% 0.0% 0.0% 5.4% 0.0% 10.0% |
|TERMINAL (d) | 0/27 (0%) 0/17 (0%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | --- --- --- 619 --- 491 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.006 ** (e) (e) P=0.159 (e) P=0.150 |
|POLY 3 | P=0.226 (e) (e) P=0.211 (e) P=0.306 |
|POLY 1.5 | P=0.284 (e) (e) P=0.220 (e) P=0.377 |
|POLY 6 | P=0.130 (e) (e) P=0.197 (e) P=0.268 |
|LOGISTIC REGRESSION| P=0.164 (e) (e) P=0.213 (e) P=0.549 |
|COCH-ARM / FISHERS | P=0.397 (e) (e) P=0.248 (e) P=0.555 |
|ORDER RESTRICTED | P=0.136 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Uterus |
| Inflammation |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 4/53 (8%) 3/51 (6%) 5/53 (9%) 7/53 (13%) 0/53 (0%) 2/66 (3%) |
|POLY-3 RATE (b) | 4/41.89 3/32.77 5/39.35 7/38.64 0/23.94 2/10.47 |
|POLY-3 PERCENT (g) | 9.6% 9.2% 12.7% 18.1% 0.0% 19.1% |
|TERMINAL (d) | 4/27 (15%) 1/17 (6%) 2/24 (8%) 2/15 (13%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 726 (T) 700 523 539 --- 415 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.020 * P=0.575 P=0.422 P=0.089 P=1.000N P=0.006 ** |
|POLY 3 | P=0.385N P=0.632N P=0.460 P=0.212 P=0.169N P=0.415 |
|POLY 1.5 | P=0.197N P=0.597N P=0.473 P=0.227 P=0.109N P=0.653N |
|POLY 6 | P=0.440 P=0.644 P=0.454 P=0.191 P=0.289N P=0.274 |
|LOGISTIC REGRESSION| P=0.500N P=0.604 P=0.455 P=0.202 (e) P=0.119 |
|COCH-ARM / FISHERS | P=0.029N* P=0.522N P=0.500 P=0.263 P=0.059N P=0.242N |
|ORDER RESTRICTED | P=0.520 (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 72
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Uterus |
| Inflammation Chronic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 2/53 (4%) 5/51 (10%) 2/53 (4%) 5/53 (9%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 2/42.77 5/34.59 2/38.44 5/38.80 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 4.7% 14.5% 5.2% 12.9% 0.0% 0.0% |
|TERMINAL (d) | 1/27 (4%) 2/17 (12%) 0/24 (0%) 1/15 (7%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 362 374 558 552 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.272N P=0.122 P=0.668 P=0.140 P=0.512N P=0.642N |
|POLY 3 | P=0.248N P=0.138 P=0.656 P=0.177 P=0.382N P=0.565N |
|POLY 1.5 | P=0.092N P=0.156 P=0.669 P=0.188 P=0.313N P=0.424N |
|POLY 6 | P=0.542N P=0.122 P=0.645 P=0.160 P=0.483N P=0.651N |
|LOGISTIC REGRESSION| P=0.005N** P=0.272 P=0.657N P=0.263 P=0.145N P=0.191N |
|COCH-ARM / FISHERS | P=0.008N** P=0.203 P=0.691N P=0.219 P=0.248N P=0.196N |
|ORDER RESTRICTED | P=0.520N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Uterus |
| Metaplasia |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 23/53 (43%) 24/51 (47%) 28/53 (53%) 24/53 (45%) 0/53 (0%) 0/66 (0%) |
|POLY-3 RATE (b) | 23/44.48 24/38.40 28/45.95 24/43.93 0/23.94 0/9.33 |
|POLY-3 PERCENT (g) | 51.7% 62.5% 60.9% 54.6% 0.0% 0.0% |
|TERMINAL (d) | 16/27 (59%) 12/17 (71%) 13/24 (54%) 7/15 (47%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 555 364 399 367 --- --- |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P=0.026N* P=0.043 * P=0.114 P=0.064 P=0.124N P=0.848N |
|POLY 3 | P<0.001N** P=0.210 P=0.242 P=0.474 P<0.001N** P=0.046N* |
|POLY 1.5 | P<0.001N** P=0.269 P=0.227 P=0.467 P<0.001N** P<0.001N** |
|POLY 6 | P=0.003N** P=0.155 P=0.263 P=0.464 P=0.002N** P=0.350N |
|LOGISTIC REGRESSION| P<0.001N** P=0.172 P=0.165 P=0.383 P<0.001N** P=0.120N |
|COCH-ARM / FISHERS | P<0.001N** P=0.429 P=0.218 P=0.500 P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.031N* (e) (e) (e) (e) (e) |
|=================================================================================================================================|
Date: 04/29/04 EXPERIMENT: 96022 TEST: 02 Page 73
Statistical Analysis of Non-neoplastic Lesions in Rats(SPRAGUE-DAWLEY) - TEF EVALUATION (PCB MIXTURE;PCB 126/P
Terminal Sacrifice at 104 weeks
|=================================================================================================================================|
| | |
| | Females |
|Dose | 0 NG / 80 NG / 240 NG / 800 NG / 2400 NG/ 4000 NG/ |
| | 0 UG 10 UG 30 UG 100 UG 300 UG 500 UG |
|=================================================================================================================================|
| |
|Uterus: Endometrium |
| Hyperplasia Cystic |
| |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|LESION RATES | |
|----------- | |
|OVERALL (a) | 32/53 (60%) 23/51 (45%) 25/53 (47%) 30/53 (57%) 7/53 (13%) 8/66 (12%) |
|POLY-3 RATE (b) | 32/46.96 23/36.64 25/45.63 30/43.41 7/26.36 8/15.68 |
|POLY-3 PERCENT (g) | 68.2% 62.8% 54.8% 69.1% 26.6% 51.0% |
|TERMINAL (d) | 21/27 (78%) 12/17 (71%) 11/24 (46%) 12/15 (80%) 0/0 (0%) 0/0 (0%) |
|FIRST INCIDENCE | 275 347 399 390 523 243 |
|-------------------| |
|STATISTICAL TESTS | |
|-------------------| |
|LIFE TABLE | P<0.001 ** P=0.431 P=0.331N P=0.059 P=0.187 P=0.003 ** |
|POLY 3 | P=0.005N** P=0.382N P=0.123N P=0.555 P<0.001N** P=0.217N |
|POLY 1.5 | P<0.001N** P=0.260N P=0.131N P=0.587N P<0.001N** P=0.003N** |
|POLY 6 | P=0.224N P=0.503N P=0.102N P=0.522 P=0.020N* P=0.462 |
|LOGISTIC REGRESSION| P<0.001N** P=0.302N P=0.141N P=0.568 P<0.001N** P=0.077N |
|COCH-ARM / FISHERS | P<0.001N** P=0.086N P=0.121N P=0.422N P<0.001N** P<0.001N** |
|ORDER RESTRICTED | P=0.050N (e) (e) (e) (e) (e) |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Number of tumor-bearing animals / Poly-3 number
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death.
Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fishers exact tests compare directly the overall incidence rates
For all tests a negative trend is indicated by N
(e) Value of Statistic cannot be computed.
(g) Poly-3 adjusted lifetime tumor incidence.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).